

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 199854134 B2**
(10) Patent No. **722089**

(54) Title
Novel benzopyran derivatives

(51)⁶ International Patent Classification(s)
C07D 311/30 A61K 031/47
A61K 031/35 C07D 221/04
A61K 031/38 C07D 335/06

(21) Application No: **199854134** (22) Application Date: **1997.12.13**

(87) WIPO No: **WO98/25916**

(30) Priority Data

(31) Number	(32) Date	(33) Country
9665301	1996.12.13	KR
9726915	1997.06.24	KR

(43) Publication Date : **1998.07.03**
(43) Publication Journal Date : **1998.09.03**
(44) Accepted Journal Date : **2000.07.20**

(71) Applicant(s)
C and C Research Laboratories

(72) Inventor(s)
Jae Chon Jo; Sung Dae Park; Hyun Suk Lim; Ju Su Kim; Sung Jin Kim; Kazumi Morikawa ; Yoshitake Kanbe; Masahiro Nishimoto; Myung-Hwa Kim

(74) Agent/Attorney
SPRUSON and FERGUSON,GPO Box 3898,SYDNEY NSW 2001

OPI DATE 03/07/98 APPLN. ID 54134/98
AOP DATE 03/09/98 PCT NUMBER PCT/KR97/00265




AU9854134

(51) International Patent Classification 6: C07D 311/30, 221/04, 335/06, A61K 31/35, 31/47, 31/38		A1	(11) International Publication Number: WO 98/25916
(21) International Application Number: PCT/KR97/00265		(43) International Publication Date: 18 June 1998 (18.06.98)	
(22) International Filing Date: 13 December 1997 (13.12.97)		KANBE, Yoshitake [JP/JP]; 1-9-10-301, Higashi-Tanaka, Gotemba-city, Shizuoka 412 (JP). NISHIMOTO, Masahiro [JP/JP]; 7-35-305, Ohmiya-cho 3-chome, Mishima-city, Sizuoka 411 (JP). KIM, Myung-Hwa [KR/KR]; 25-3-303, Hagiwara, Gotemba-city, Sizuoka 412 (KR).	
(30) Priority Data: 1996/65301 13 December 1996 (13.12.96) KR 1997/26915 24 June 1997 (24.06.97) KR		(74) Agents: CHOI, Kyu, Pal et al.; 824-20, Yeoksam-dong, Kangnam-ku, Seoul 135-080 (KR).	
(71) Applicant (for all designated States except US): C & C RESEARCH LABORATORIES [KR/KR]; 146-141, Annyung-ri, Tae-an-ub, Hwasung-gun, Kyunggi-do 445-970 (KR).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(72) Inventors; and (75) Inventors/Applicants (for US only): JO, Jae, Chon [KR/KR]; Samhwan Apartment, #1-810, Kuwoon-dong, Kwon-sun-gu, Suwon-shi, Kyunggi-do 441-340 (KR). PARK, Sung, Dae [KR/KR]; Jamwon Family Apartment, #1-1006, Jamwon-dong, Seocho-gu, Seoul 137-030 (KR). LIM, Hyun, Suk [KR/KR]; Jugong Apartment, #525-503, Maetan-dong, Paldal-gu, Suwon-shi, Kyunggi-do 442-370 (KR). KIM, Ju, Su [KR/KR]; 777-1, Bono-dong, Ansan-shi, Kyunggi-do 425-180 (KR). KIM, Sung, Jin [KR/KR]; 918-7, Juan 6-dong, Nam-gu, Incheon 402-206 (KR). MORIKAWA, Kazumi [JP/JP]; 5-2, Higashi-Ichouda, Mishima-city, Sizuoka 411 (JP).		Published With international search report.	
(54) Title: NOVEL BENZOPYRAN DERIVATIVES			
(57) Abstract			
The present invention relates to a novel benzopyran derivative having anti-estrogenic activity. More specifically, the present invention relates to a novel benzopyran derivative represented by formula (I) and pharmaceutically acceptable salt thereof, in which --- represents a single bond or a double bond; R_1 and R_2 independently of one another represent hydrogen, hydroxy or OR group, wherein R represents acyl or alkyl; R_3 represents hydrogen, lower alkyl or halogeno lower alkyl, provided that when --- represents a double bond, R_3 is not present; R_4 represents hydrogen or lower alkyl; A represents a group of formula (a), (b), (c) or (d); R_5, R_6 and R_7 independently of one another represent hydrogen, alkyl, halogenoalkyl, alkenyl or halogenoalkenyl, or R_6 and R_7 together with nitrogen atom to which they are bound can form a 4- to 8-membered heterocyclic ring which can be substituted with R_5; X represents O, S or NR_8, wherein R_8 represents hydrogen or lower alkyl; m denotes an integer of 2 to 15; n denotes an integer of 0 to 2; and p denotes an integer of 0 to 4, and to a process for preparation thereof and a pharmaceutical composition having anti-estrogenic activity which contains the compound (I) as an active component.			
		(I)	
		(a)	
		(b)	
		(c)	
		(d)	

NOVEL BENZOPYRAN DERIVATIVES

TECHNICAL FIELD

The present invention relates to a novel benzopyran derivative having anti-estrogenic activity. More specifically, the present invention relates to a novel benzopyran derivative represented by formula (I):



and pharmaceutically acceptable salt thereof, in which

----- represents a single bond or a double bond;





R₁ and R₂ independently of one another represent hydrogen, hydroxy or OR group, wherein R represents acyl or alkyl;

R₃ represents hydrogen, lower alkyl or halogeno lower alkyl, provided that

when ----- represents a double bond, R₃ is not present;

R₄ represents hydrogen or lower alkyl;

A represents a group of formula (a), (b), (c) or (d);



R₅, R₆ and R₇ independently of one another represent hydrogen, alkyl, halogenoalkyl, alkenyl or halogenoalkenyl, or

R₆ and R₇ together with nitrogen atom to which they are bound can form a 4- to 8-membered heterocyclic ring which can be substituted with R₅;

X represents O, S or NR₈, wherein R₈ represents hydrogen or lower alkyl;

m denotes an integer of 2 to 15;

n denotes an integer of 0 to 2; and

p denotes an integer of 0 to 4,

and to a process for preparation thereof and a pharmaceutical composition having anti-estrogenic activity which contains the compound (I) as an active component.


BACKGROUND ART


In treating diseases caused by the abnormal tissue growth depending on a certain sexual steroidal hormone such as estrogen, it is very important to significantly inhibit, if possible, to completely remove the effect induced by said sexual steroidal hormone. For this purpose, it is desirable to block the receptor site which can be stimulated by sexual steroidal hormone and further, to reduce the level of sexual steroidal hormone capable of acting on said receptor site. For instance, as a substitution or combined therapy, administration of anti-estrogenic agents to limit the production of estrogen to the amount less than required to activate the receptor site may be used. However, prior methods for blocking the estrogen production could not sufficiently inhibit the effect induced through estrogen receptor. Practically, even when estrogen is completely absent, some of the receptors may be activated. Accordingly, it was considered that antagonists for estrogen can provide better therapeutic effect in comparison to the method for blocking only the production of sexual steroidal hormone. Thus, numerous anti-estrogenic compounds have been developed. For example, many patent publications including U.S. Patent Specifications 4,760,061, 4,732,912, 4,904,661 and 5,395,842 and WO 96/22092, etc. disclose various anti-estrogenic compounds.

However, prior antagonists have sometimes insufficient affinity to the receptors. In some cases, moreover, they can combine to the receptor but act themselves as agonists, and therefore, activate rather than block the receptor. For example, Tamoxifen has been most widely used as an anti-estrogenic agent. However, it has a disadvantage that it exhibits estrogenic activity in some organs (see, M. Harper and A. Walpole, J. Reprod. Fertil., 1967, 13, 101). Therefore, it is required to develop the anti-estrogenic compound which has substantially or completely no agonistic effect and can effectively block the estrogenic receptor.


In addition, it has been known that 7α -substituted derivatives of estradiol, for example, 7α -(CH₂)₁₀CONMeBu derivative, exhibit anti-estrogenic activity (see, EP Appl. 0138504, USP 4,659,516). Further, estradiol derivative having -(CH₂)₉SOC₅H₆F₅ substituent has also been disclosed (see, Wakeling et al., Cancer Res., 1991, 51, 3867) as steroidal anti-estrogen without agonistic effect.

Non-steroidal anti-estrogenic drug without agonistic effect has been first reported by Wakeling et al. in 1987 (see, A. Wakeling and J. Bowler, J. Endocrinol., 1987, 112, R7). Meanwhile, U.S. Patent Specification 4,904,661 (ICI, Great Britain) discloses a phenol derivative having anti-estrogenic activity. This phenol derivative generally has a naphthalene structure and includes, typically, the following compounds:






As other non-steroidal anti-estrogenic compounds, WO 93/10741 discloses benzopyran derivatives having aminoethoxyphenyl substituent (Endorecherche), of which the typical compound is EM-343 having the following structure:



Accordingly, the present inventors have researched the anti-estrogenic activity of compounds having various structures. As a result, we have identified that the benzopyran derivatives represented by formula (I), as defined above, can exhibit a good anti-estrogenic activity without agonistic activity, to be expected no undesirable side effect and thus, completed the present invention.

DISCLOSURE OF THE INVENTION

Therefore, the present invention relates to a novel benzopyran derivative represented by formula (I):



and pharmaceutically acceptable salt thereof, in which

==== represents a single bond or a double bond;





R₁ and R₂ independently of one another represent hydrogen, hydroxy or OR group, wherein R represents acyl or alkyl;

R₃ represents hydrogen, lower alkyl or halogeno lower alkyl, provided that

when ---- represents a double bond, R₃ is not present;

R₄ represents hydrogen or lower alkyl;

A represents a group of formula (a), (b), (c) or (d);



R₅, R₆ and R₇ independently of one another represent hydrogen, alkyl, halogenoalkyl, alkenyl or halogenoalkenyl, or

R₆ and R₇ together with nitrogen atom to which they are bound can form a 4- to 8-membered heterocyclic ring which can be substituted with R₅;

X represents O, S or NR₈, wherein R₈ represents hydrogen or lower alkyl;

m denotes an integer of 2 to 15;

n denotes an integer of 0 to 2; and

p denotes an integer of 0 to 4.

In addition, the present invention also relates to a process for preparing the benzopyran derivative of formula (I).

Further, the present invention relates to a pharmaceutical composition having anti-estrogenic activity, which contains the compound of formula (I) as an active component.

BEST MODE FOR CARRYING OUT THE INVENTION

In the present specification, the term "lower alkyl" denotes straight or branched saturated hydrocarbon radicals having 1 to 6, preferably 1 to 4, carbon atoms; the term "halogeno lower alkyl" denotes straight or branched saturated hydrocarbon radicals having 1 to 6, preferably 1 to 4, carbon atoms and 1 to 9, preferably 1 to 5, halogen atoms such as fluorine, chlorine, bromine, etc, preferably fluorine atom; the term "alkyl" denotes straight or branched saturated hydrocarbon radicals having 1 to 10, preferably 1 to 6, carbon atoms including lower alkyl as defined above; and the term "alkenyl" denotes straight or branched hydrocarbon radicals having 2 to 10, preferably 2 to 6, carbon atoms and one or more double bond(s). Further, the term "4- to 8-membered heterocyclic ring" denotes saturated or unsaturated heteromono-cyclic ring which can contain 1 to 4 nitrogen atoms and includes, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, triazinyl, pyridazinyl, triazolyl, tetrazolyl, piperazinyl, piperidino, pyrrolidinyl, imidazolidinyl, etc.

In the compound of formula (I) according to the present invention, preferably R₁ and R₂ independently of one another represent hydrogen, hydroxy or OR wherein R represents acyl or alkyl, R₃ represents hydrogen, C₁-C₄ lower alkyl or halogeno-C₁-C₄ lower alkyl, R₄ represents hydrogen or C₁-C₄ lower alkyl, A represents a group of formula (a), (b), (c) or (d), R₅, R₆ and R₇ independently of one another represent hydrogen, C₁-C₆ alkyl, halogeno-C₁-C₆ alkyl, C₂-C₆ alkenyl or halogeno-C₂-C₆ alkenyl, or R₆ and R₇ together with

nitrogen atom to which they are bound can form a 5- to 6-membered heterocyclic ring which can contain 1 to 2 nitrogen atoms and can be substituted with halogeno-C₁-C₆ alkyl, X represents O, S or NR₈, wherein R₈ represents hydrogen or C₁-C₄ lower alkyl, m denotes an integer of 4 to 12, n denotes an integer of 0 to 2 and p denotes an integer of 1 to 3.

Particularly preferable compound of formula (I) according to the present invention includes those wherein R₁ and R₂ independently of one another represent hydrogen or hydroxy, R₃ represents hydrogen or C₁-C₂ lower alkyl, R₄ represents hydrogen or C₁-C₂ lower alkyl, A represents a group of formula (a), (b), (c) or (d), R₅, R₆ and R₇ independently of one another represents hydrogen, C₁-C₆ alkyl or halogeno-C₁-C₆ alkyl, or R₆ and R₇ together with nitrogen atom to which they are bound can form piperazinyl or piperidino group which can be substituted with halogeno-C₁-C₆ alkyl, X represents O or S, m denotes an integer of 4 to 12, n denotes an integer of 0 to 2 and p denotes an integer of 2.

As specific example of the compound of formula (I) according to the present invention, the following compounds can be mentioned:

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylthio)octyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylsulfinyl)octyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfonyl)nonyl]-2,3-dihydro-4H-benzopyran;

7-hydroxy-3-(4-hydroxyphenyl)-4-[4-(5-(4,4,5,5,5-pentafluoropentylthio)pentyl)-phenyl]-2H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-thiochroman;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylthio)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylsulfinyl)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylsulfonyl)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(2-piperidinoethylthio)-nonyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(2-piperidinoethylsulfinyl)-nonyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(5-(4,4,5,5,5-pentafluoropentylthio)pentylloxy)phenyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(5-(4,4,5,5,5-pentafluoropentylsulfinyl)pentylloxy)phenyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(5-(4,4,5,5,5-pentafluoropentylsulfonyl)pentylloxy)phenyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-(piperidinoethyloxy)phenyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-(5-(4,4,5,5,5-pentafluoropentylsulfonyl)pentylloxy)phenyl]thiochroman;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-(4-piperidinobutyloxy)phenyl]thiochroman or its hydrochloride;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-[2-(4-(4,4,5,5,5-pentafluoropentyl)piperazino)ethyloxy]phenyl]thiochroman dihydrochloride;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylsulfinyl)octyl]thiochroman;


(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[10-(4,4,5,5,5-pentafluoropentylsulfinyl)decyl]thiochroman;

(3RS,4RS)-7-hydroxy-3-phenyl-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]thiochroman;


(3RS,4RS)-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]thiochroman;
(3RS,4RS)-7-methoxy-3-(4-methoxyphenyl)-3-methyl-4-(9-pentylthiononyl)thiochroman;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-(9-pentylthiononyl)thiochroman;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-(9-pentylsulfinynonyl)thiochroman;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman; and
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman.

The present invention also provides a process for preparing the compound of formula (I) as defined above. According to the present invention, the compound of formula (I) can be prepared by a method depicted in anyone of the following reaction schemes I, II, III, IV, V, VI and VII.


Reaction Scheme I (Process 1)




Reaction Scheme II (Process 2)




Reaction Scheme III (Process 3)




Reaction Scheme IV (Process 4)




Reaction Scheme V (Process 5)



Reaction Scheme VI (Process 6)



Reaction Scheme VII (Process 7)



In the above reaction schemes I, II, III, IV, V, VI and VII

—, R, R_1 to R_8 , X, m and n are defined as in formula (I),

R_9 represents methyl or tolyl,

P represents hydrogen or hydroxy protected by a conventional hydroxy-protecting group such as methoxymethyl or t-butyldimethylsilyl,

W represents R_5 or $-(\text{CH}_2)_p-\text{N}(\text{R}_6)(\text{R}_7)$, wherein R_5 , R_6 , R_7 and p are defined as in formula (I),

Z represents halogen,

Y represents halogen or hydroxy,

q denotes an integer of m-2, and

TBS denotes t-butyldimethylsilyl group and TMS denotes trimethylsilyl group.

Hereinafter, the process of the present invention will be more specifically explained.

Process 1

According to the process 1 of the present invention for preparing the compound of formula (I), in the first reaction step a compound of formula (VIII) is reacted with a compound of formula (IX) to produce a compound of formula (VII). This reaction can preferably be carried out in the presence of a solvent. Although any of organic solvents which do not adversely affect the reaction can be used as the solvent in this reaction, the reaction is preferably carried out in the solvent such as tetrahydrofuran, ethyl ether, dioxane, hexane, etc., with tetrahydrofuran being particularly preferable. The reaction is preferably conducted under anhydrous condition. The reaction temperature is not specifically limited and the reaction can be generally carried out under cooling to warming, preferably at room temperature.

In the second reaction step, the compound of formula (VII) produced in the first reaction step is reduced to produce a compound of formula (VIC). This reduction can be practiced by means of any of conventional reduction methods, for example, using a combination of metal and organic or inorganic acid or by catalytic reduction in the presence of a metallic catalyst. This reaction is actually conducted in the manner that the compound (VII) is reduced with sodium cyanoborohydride and zinc iodide to produce a compound of formula (VIA) and then the compound of formula (VIA) is reduced using Pd/C to produce a compound of formula (VIB) which is then treated with pyridinium p-toluenesulfonate (PPTS) to obtain the compound (VIC).

The reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, ethyl acetate, methanol, ethanol, etc., with ethyl acetate being particularly preferable. The reaction temperature is not specifically limited and the reaction can be generally carried out under cooling to warming.

In the third reaction step, the compound of formula (VI) produced in the second reaction step is reacted with a compound of formula (V) to produce a compound of formula (IV). This reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, pyridine, dichloromethane, ethyl acetate, tetrahydrofuran, ethyl ether, chloroform, etc., with pyridine and dichloromethane being particularly preferable. The reaction temperature is not specifically limited and the reaction can be generally carried out under cooling to warming.

In the fourth reaction step, the compound of formula (IV) produced in the third reaction step is reacted with a compound of formula (III) to produce a compound of formula (II). The reaction is preferably carried out in the presence of a base. The base which can be preferably used for this purpose includes, for example, sodium hydroxide, sodium methoxide, potassium hydroxide, sodium ethoxide, etc., with sodium hydroxide being particularly preferable. The reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, methanol, ethanol, tetrahydrofuran, dioxane, etc., with methanol being particularly preferable.

In the fifth reaction step, the compound of formula (II) produced in the fourth reaction step wherein P represents protected hydroxy group, is subsequently deprotected to produce a compound of formula (Ia). The deprotection can be conducted according to a conventional deprotection method

such as hydrolysis in the presence of acid or base, reduction, and the like.

If desired, in the sixth reaction step, the compound of formula (Ia) thus produced is alkylated or esterified according to a conventional method to produce a compound of formula (Ib) wherein R represents acyl or alkyl.

In addition, the compound of formula (I), wherein n is 0, produced according to the process 1 can be converted into the corresponding sulfinyl or sulfonyl compound wherein n is 1 or 2 according to a conventional oxidation method. As the oxidizing agent suitable for this reaction, for example, sodium periodate (NaIO_4), metachloroperbenzoic acid, hydrogen peroxide, oxone, etc. can be preferably used. The reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, methanol, dioxane, water, ethanol, tetrahydrofuran, etc.

The desired compound produced in this process can be separated and purified according to a conventional method such as column chromatography, recrystallization, etc.

Process 2

According to the process 2 of the present invention for preparing the compound of formula (I), in the first reaction step the compound of formula (VIII) is reacted with a compound of formula (XIV) to produce a compound of formula (XIII). This reaction is carried out in the presence of magnesium so that the compound (XIV) can first be reacted with magnesium to form a Grignard reagent and the resulting Grignard reagent is then reacted with the compound of formula (VIII). The reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes tetrahydrofuran, ethyl ether, dioxane, etc. The reaction is preferably conducted under

anhydrous condition. The reaction is generally carried out under cooling, preferably at -78°C to room temperature.

In the second reaction step, the compound of formula (XIII) produced in the first reaction step is reacted with a compound of formula (XII) to produce a compound of formula (XI). This reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, acetone, methyl ethyl ketone, tetrahydrofuran, ethyl acetate, dioxane, etc. The reaction is generally carried out under reflux.

In view of the reaction efficiency in the next reaction step, if necessary, it may be preferable to convert the compound wherein Y is hydroxy or halogen such as chloro, except iodo, into the compound wherein Y is iodo by reacting with an iodizing agent such as sodium iodide.

In the third reaction step, the compound of formula (XI) produced in the second reaction step is reacted with a compound of formula (IIIa) to produce a compound of formula (X). This reaction is carried out under the same condition as in the fourth reaction step of the process 1.

The compound of formula (X) thus produced is subsequently deprotected to produce a compound of formula (Ic). If desired, the resulting compound of formula (Ic) is then alkylated or esterified to produce a compound of formula (Id). This reaction is carried out under the same condition as in the fifth and sixth reaction steps of the process 1.

In addition, the compound of formula (I), wherein n is 0, produced according to the process 2 can be oxidized according to a conventional method to convert into the corresponding sulfinyl or sulfonyl compound wherein n is 1 or 2, as mentioned in the process 1.

The desired compound produced in this process can be separated and purified according to a conventional method such as column chromatography, recrystallization, etc.

Process 3

According to another process 3 of the present invention for preparing the compound of formula (I), the compound of formula (XI) is reacted with an amino compound of formula (XVI) to produce a compound of formula (XV), which is then deprotected and optionally alkylated or esterified according to the same procedures as the fifth and sixth reaction steps of the process 1 to produce a compound of formulae (Ie) and (If). The reaction between the compound of formula (XI) and the compound of formula (XVI) is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, chloroform, ethyl acetate, dichloromethane, tetrahydrofuran, etc. The reaction temperature is not specifically limited and the reaction can be generally carried out under cooling to warming.

The desired compound produced in this process can be separated and purified according to a conventional method such as column chromatography, recrystallization, etc.

Process 4

According to the process 4 of the present invention for preparing the compound of formula (Ig), in the first reaction step a compound of formula (VIII) is reacted with a compound of formula (XVI) to produce a compound of formula (XVII). This reaction is carried out in the presence of magnesium so that the compound (XVI) can first be reacted with magnesium to form a Grignard reagent and the resulting Grignard reagent is then reacted with the compound of formula (VIII). The reaction is generally carried out in the

presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes tetrahydrofuran, ethyl ether, dioxane, etc. The reaction is preferably conducted under anhydrous condition. The reaction is generally carried out under refluxing temperature.

In the second reaction step, the compound of formula (XVII) produced in the first reaction step is reduced to produce a compound of formula (XVIII). This reaction can be practiced by means of any conventional method, for example, sodium cyanoborohydride, lithium aluminumhydride, etc., with Lewis acid such as zinc iodide, iron (III) chloride, trifluoroborane etherate, etc. The reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, dichloromethane, 1,2-dichloroethane, chloroform, etc., with dichloromethane being particularly preferable.

In the third reaction step, the compound of formula (XVIII) produced in the second reaction step is deprotected to produce a compound of formula (XIX). The deprotection can be conducted according to a conventional deprotecting method with tetra-n-butylammonium fluoride, hydrogen chloride, hydrogen fluoride, etc. The reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, tetrahydrofuran, ethyl ether, dichloromethane, etc., with tetrahydrofuran being particularly preferable.

In the fourth reaction step, the compound of formula (XIX) produced in the third reaction step is reacted with a compound of formula (XX) to produce a compound of formula (XXI). This reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, dimethylformamide, toluene, 2-butanone, tetrahydrofuran, acetone,

dioxane, etc. The reaction is generally carried out under refluxing in the presence of a base such as potassium carbonate, sodium hydroxide, cesium carbonate, and crown ether.

In the fifth reaction step, the compound of formula (XXI) produced in the fourth reaction step wherein P represents protected hydroxy group, is subsequently deprotected to produce a compound of formula (I_g). The deprotection can be conducted under the same condition as in the fifth reaction step of the process 1.

Process 5

According to the process of the present invention for preparing the compound of formula (XX), in the first reaction step a compound of formula (XXII) is reacted with a compound of formula (XXIII) to produce a compound of formula (XXIV). The reaction is preferably carried out in the presence of a base. The base which can be preferably used for this purpose includes, for example, sodium hydroxide, sodium methoxide, potassium hydroxide, sodium ethoxide, etc., with sodium hydroxide being particularly preferable. The reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, methanol, ethanol, tetrahydrofuran, dioxane, etc., with methanol being particularly preferable.

In the second reaction step, the compound of formula (XXIV) produced in the first reaction step is oxidized to produce a compound of formula (XX). As the oxidizing agent suitable for this reaction, for example, sodium periodate (NaIO₄), metachloroperbenzoic acid, hydrogen peroxide, oxone, etc. can be preferably used. The reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, methanol, dioxane, water, ethanol, tetrahydrofuran, etc.

Process 6

According to the process 6 of the present invention for preparing the compound of formulae (XXVIII) and (XXIX), in the first reaction step a compound of formula (XXV) is reacted with a compound of formula (XII) to produce a compound of formula (XXVI). This reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, acetone, 2-butanone, tetrahydrofuran, ethyl acetate, dichloromethane, chloroform, etc., with acetone and 2-butanone being particularly preferable. The reaction temperature is not specifically limited and the reaction can be generally carried out under heating.

In the second reaction step, the compound of formula (XXVI) produced in the first reaction step is reacted with an amino compound of formula (XVI) to produce a compound of formula (XXVII), which is then deprotected and optionally alkylated or esterified according to the same procedures as the fifth and sixth reaction steps of the process 1 to produce a compound of formulae (Ia) and (Ib). The reaction between the compound of formula (XXVI) and the compound of formula (XVI) is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, ethanol, isopropanol, t-butanol, tetrahydrofuran, dichloromethane, chloroform, etc., with ethanol and isopropanol being particularly preferable. The reaction temperature is not specifically limited and the reaction can be generally carried out under heating.

The desired compound produced in this process can be separated and purified according to a conventional method such as column chromatography, recrystallization, etc.

Process 7

The process 7 depicted in the reaction scheme VII is a method for preparing the chromanon derivative of formula (6) which is the starting compound required for preparing the compound of formula (I) wherein X is S. The specific method and reaction conditions refer to Example 57 described hereinafter.

As stated above, the compound of formula (I) prepared according to the process of the present invention as mentioned above has a good anti-estrogenic activity and, therefore, can be used for treatment of estrogen-related diseases including anovular infertility, breast cancer, endometrial cancer, uterine cancer, ovarian cancer, endometriosis, endometrial fibroma, benign prostate hypertrophy, precocious puberty, menstrual disorder, etc.

Therefore, the present invention relates to an anti-estrogenic pharmaceutical composition containing the compound of formula (I) as an active component.

When the anti-estrogenic pharmaceutical composition containing the compound of the present invention as an active component is used for clinical purpose, it can be formulated into a conventional preparation in the pharmaceutical field, for example, preparation for oral administration such as tablet, capsule, troche, solution, suspension, etc., or injectable preparation such as injectable solution or suspension, ready-to-use injectable dry powder which can be reconstituted with distilled water for injection when it is injected, etc., by combining with a carrier conventionally used in the pharmaceutical field

Suitable carrier which can be used in the composition of the present invention includes those conventionally used in the pharmaceutical field, for example, binder, lubricant, disintegrant, excipient, solubilizer, dispersing agent, stabilizing agent, suspending agent, colouring agent, perfume, etc. for oral preparation; and preservative, pain alleviating agent, solubilizing agent, stabilizing agent, etc. for injectable preparation. The pharmaceutical



preparation thus prepared can be administered orally or parenterally, for example, intravenously, subcutaneously or intraperitoneally. In addition, in order to prevent the active component from the decomposition with gastric acid, the oral preparation can be administered together with an antacid or in the enteric-coated form of the solid preparation such as tablet.

The dosage of the benzopyran derivative of formula (I) according to the present invention for human being can be suitably determined depending on absorption, inactivation and secretion of the active ingredient in the human body, age, sex and condition of subject patient, kinds and severity of disease to be treated. It is generally suitable to administer the compound of formula (I) in an amount of 1 to 500mg, preferably 5 to 200mg, per day for adult patient.

The present invention is more specifically explained by the following examples. However, it should be understood that the present invention is not limited to these examples in any manner.

Example 1

Synthesis of 7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran-4-one

7-Hydroxy-3-(4-hydroxyphenyl)-2,3-dihydro-4H-benzopyran-4-one (1.9g, 5.5 mmol) and methyl iodide (20.5ml, 60 equ.) were added to dry tetrahydrofuran (20ml) under argon atmosphere and the mixture was cooled to -78°C. 2.0M Lithium diisopropylamide (LDA) (4.2ml) was slowly added dropwise thereto. Then the reaction mixture was slowly warmed to -20°C with stirring and water was added thereto at the same temperature. The reaction solution was extracted with dichloromethane, dried over magnesium sulfate and then concentrated. The residue was subjected to column chromatography (n-hexane: ethyl acetate = 8:1) to obtain 1.3g (yield: 66%) of the title compound as a colorless oil.

¹H-NMR(300MHz, CDCl₃) : δ 7.87(d, 1H), 7.33(dd, 2H), 6.97(dd, 2H), 6.65(dd, 1H), 6.53(d, 1H), 5.16(s, 2H), 5.13(s, 2H), 4.81(d, 1H), 4.32(d, 1H), 3.45(s, 3H), 3.45(s, 3H), 1.45(s, 3H)

Example 2

Synthesis of (3RS,4RS)-4-[9-(t-butyldimethylsilyloxy)nonyl]-4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran

9-(t-Butyldimethylsilyloxy)-non-1-yne (0.46g, 1.8 mmol) was dissolved in dry tetrahydrofuran (8ml) under argon atmosphere and then cooled to -78°C. 2.5M n-Butyllithium (n-BuLi) (0.7ml, 1.68 mmol) was slowly added dropwise thereto and then the mixture was stirred for 30 minutes. To the mixture was added dropwise 7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran-4-one (200mg, 6.6 mmol) dissolved in dry tetrahydrofuran (4ml), and then the reaction mixture was slowly warmed to room temperature. The reaction solution was quenched with water and then extracted with ethyl acetate. The organic layer was separated, dried over magnesium sulfate and concentrated. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 350mg (yield: >100%) of the title compound as a colorless oil.

Example 3

Synthesis of (3RS,4RS)-4-(9-hydroxynonyl)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran

(3RS,4RS)-4-[9-(t-Butyldimethylsilyloxy)nonyl]-4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran (340mg, 0.56 mmol) was dissolved in ethyl acetate (10ml) and then 10% Pd/C (180mg) was added dropwise thereto. The reaction solution was stirred for 15 hours under hydrogen atmosphere, filtered and then concentrated. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 4:1→1:1) to

obtain 90mg (yield: 33%) of the title compound as a colorless oil.

¹H-NMR(300MHz, CDCl₃) : δ 7.05(d, 2H), 6.96(d, 2H), 6.88(d, 1H), 6.49(m, 2H), 5.10(s, 2H), 5.07(s, 2H), 4.45(d, 1H), 4.18(d, 1H), 3.53(t, 2H), 3.42(s, 6H), 2.55(m, 1H), 1.44(m, 2H), 1.23-0.99(brs, 17H)

Example 4

Synthesis of (3RS,4RS)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-4-[9-(p-toluenesulfonyloxy)nonyl]-2,3-dihydro-4H-benzopyran

(3RS,4RS)-4-(9-Hydroxynonyl)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran (90mg, 0.19 mmol) was dissolved in pyridine (2mℓ) and dichloromethane (0.5mℓ) and then cooled to 0°C. p-Toluenesulfonylchloride (0.12g, 0.63 mmol) was added dropwise thereto, and the mixture was stirred for 3 hours at room temperature, quenched with water and then extracted with ethyl acetate. The extracted organic substance was washed with 2N hydrochloric acid, dried over magnesium sulfate and then concentrated. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 105mg (yield: 88%) of the title compound as a colorless oil.

¹H-NMR(300MHz, CDCl₃) : δ 7.71(dd, 2H), 7.25(d, 2H), 7.10(d, 2H), 6.95(d, 2H), 6.88(m, 1H), 6.49(m, 2H), 5.10(s, 2H), 5.06(s, 2H), 4.45(d, 1H), 4.18(d, 1H), 3.60(t, 2H), 3.41(s, 6H), 2.56(m, 1H), 2.35(s, 3H), 1.51(m, 2H), 1.17-0.99 (m, 17H)

Example 5

Synthesis of (3RS,4RS)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-2,3-dihydro-4H-benzopyran

4,4,5,5,5-Pentafluoropentylthioacetate (0.21g, 0.9 mmol) was dissolved in

methanol (5mℓ) and 2N aqueous sodium hydroxide solution (0.8mℓ) was added thereto. The reaction solution was stirred for 30 minutes at room temperature and (3RS,4RS)-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-4-[9-(p-toluenesulfonyloxy)nonyl]-2,3-dihydro-4H-benzopyran (100mg, 0.2 mmol) dissolved in methanol (2mℓ) was added thereto. The reaction mixture was stirred for one hour at 60°C and then cooled. After adding water, the reaction solution was extracted with ethyl acetate and the organic layer was dried over magnesium sulfate and concentrated. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 7:1) to obtain 100mg (yield: 97%) of the title compound as a colorless oil.

¹H-NMR(300MHz, CDCl₃) : δ 7.16(d, 2H), 7.06(d, 2H), 6.98(d, 1H), 6.60(m, 2H), 5.21(s, 2H), 5.18(s, 2H), 4.55(d, 1H), 4.29(d, 1H), 3.52(s, 6H), 2.65(m, 1H), 2.60(t, 2H), 2.51(t, 2H), 2.15(m, 2H), 1.95(m, 2H), 1.57(m, 2H), 1.35-1.10(m, 17H)

Example 6

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-2,3-dihydro-4H-benzopyran

(3RS,4RS)-7-Methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-2,3-dihydro-4H-benzopyran (100mg, 0.15 mmol) and pyridinium p-toluenesulfonate (380mg, 1.5 mmol) were dissolved in methanol (5mℓ) and refluxed for 4 hours. The reaction solution was cooled to room temperature and, after adding water, extracted with ethyl acetate. The extracted organic layer was dried over magnesium sulfate and concentrated. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 57mg (yield: 66%) of the title compound as a colorless oil.

¹H-NMR(300MHz, CDCl₃) : δ 7.02(d, 2H), 6.83(d, 1H), 6.75(d, 2H), 6.29(m, 2H), 4.42(d, 1H), 4.14(d, 1H), 2.90(m, 1H), 2.53(t, 2H), 2.44(t, 2H),

2.20(m, 2H), 1.81(m, 2H), 1.48(m, 2H), 1.21-1.02(m, 17H)

Example 7

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-2,3-dihydro-4H-benzopyran

(3RS,4RS)-7-Hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-2,3-dihydro-4H-benzopyran (47mg, 0.08 mmol) was dissolved in 1,4-dioxane (1ml), methanol (1ml) and water (0.25ml). NaIO₄ (20mg, 0.093 mmol) was added dropwise thereto, and the reaction mixture was stirred for 12 hours at room temperature and then filtered. The filtrate was concentrated and the residue was subjected to column chromatography (n-hexane:ethyl acetate = 3:1→1:1) to obtain 35mg (yield: 73%) of the title compound as a colorless oil.

¹H-NMR(300MHz, CDCl₃) : δ 7.05(d, 2H), 6.85(d, 1H), 6.80(d, 2H), 6.32(s, 2H), 5.20(s, 1H), 5.16(s, 1H), 4.48(d, 1H), 4.20(dd, 1H), 2.72(m, 2H), 2.56(m, 1H), 2.23(m, 4H), 1.76(m, 2H), 1.30(m, 2H), 1.21-0.90(m, 19H)

MS : 591(M+1)

Example 8

Synthesis of (3RS,4RS)-4-[8-(t-butyldimethylsilyloxy)octynyl]-4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran

8-(t-Butyldimethylsilyloxy)oct-1-yne (0.6g, 2.5 mmol) was dissolved in dry tetrahydrofuran (8ml) under argon atmosphere and then cooled to -78°C. 2.5M n-BuLi (0.94ml, 2.35 mmol) was slowly added dropwise thereto and then the mixture was stirred for 30 minutes. To the mixture was added dropwise 7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran-4-one (300mg, 0.84 mmol) dissolved in dry tetrahydrofuran (4ml), and then the reaction mixture was slowly warmed to room temperature. After 3

hours, water was added to the reaction mixture. The reaction solution was extracted with ethyl acetate and the organic layer was dried over magnesium sulfate. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 500mg (yield: ~100%) of the title compound as a colorless oil.

Example 9

Synthesis of (3RS,4RS)-4-(8-hydroxyoctyl)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran

(3RS,4RS)-4-[8-(t-Butyldimethylsilyloxy)octynyl]-4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran (500mg, 0.84 mmol) was dissolved in ethyl acetate (14ml) and then 10% Pd/C (230mg) was added thereto. The reaction mixture was stirred under hydrogen atmosphere. After 5 hours, the reaction solution was filtered and then concentrated. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 4:1→1:1) to obtain 80mg (yield: 33%) of the title compound as a colorless oil.

Example 10

Synthesis of (3RS,4RS)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-4-[8-(p-toluenesulfonyloxy)octyl]-2,3-dihydro-4H-benzopyran

(3RS,4RS)-4-(8-Hydroxyoctyl)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran (80mg, 0.17 mmol) was dissolved in pyridine (2ml) and dichloromethane (0.5ml) and then cooled to 0°C. p-Toluenesulfonylchloride (0.12g, 0.63 mmol) was added thereto and the mixture was stirred for 6 hours at room temperature. Water was added thereto at 0°C and the reaction solution was extracted with ethyl acetate, washed with saturated saline and then dried over magnesium sulfate. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 110mg (yield: ~100%) of the title compound as a colorless oil.

Example 11**Synthesis of (3RS,4RS)-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylthio)octyl]-2,3-dihydro-4H-benzopyran**

4,4,5,5,5-Pentafluoropentylthioacetate (0.28g, 1.2 mmol) was dissolved in methanol (5mℓ) and 2N aqueous sodium hydroxide solution (1mℓ) was added thereto. The reaction solution was stirred for 40 minutes at room temperature and (3RS,4RS)-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-4-[8-(p-toluenesulfonyloxy)octyl]-2,3-dihydro-4H-benzopyran (100mg, 0.2 mmol) dissolved in methanol (2mℓ) was added thereto. The reaction mixture was stirred for 2 hours at 60°C and then cooled. After adding water, the reaction solution was extracted with ethyl acetate and the organic layer was dried over magnesium sulfate and concentrated. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 8:1) to obtain 120mg (yield: ~100%) of the title compound as a colorless oil.

¹H-NMR(300MHz, CDCl₃) : δ 7.16(d, 2H), 7.10(d, 2H), 6.97(d, 1H), 6.60(m, 2H), 5.21(s, 2H), 5.18(s, 2H), 4.55(d, 1H), 4.30(d, 1H), 3.52(s, 6H), 2.65(m, 1H), 2.60(t, 2H), 2.52(t, 2H), 2.20(m, 2H), 1.91(m, 2H), 1.53(m, 2H), 1.32-1.10 (m, 15H)

Example 12**Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylthio)octyl]-2,3-dihydro-4H-benzopyran**

(3RS,4RS)-7-Methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylthio)octyl]-2,3-dihydro-4H-benzopyran (120mg, 0.19 mmol) and pyridinium p-toluenesulfonate (580mg, 2.3 mmol) were dissolved in methanol (8mℓ) and then refluxed for 7 hours. The reaction solution was cooled to room temperature and, after adding water, extracted with ethyl acetate. The organic layer was separated, washed with water, dried over magnesium sulfate and then concentrated. The residue was subjected to

column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 64mg (yield: 69%) of the title compound as a colorless oil.

¹H-NMR(300MHz, CDCl₃) : δ 7.01(dd, 2H), 6.83(d, 1H), 6.77(d, 2H), 6.30(d, 2H), 4.96(s, 1H), 4.76(s, 1H), 4.44(d, 2H), 4.18(d, 2H), 2.51(m, 3H), 2.40(t, 2H), 2.05(m, 2H), 1.81(m, 2H), 1.44(m, 2H), 1.21-0.98(m, 15H)

MS : 561(M+1)

Example 13

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylsulfinyl)octyl]-2,3-dihydro-4H-benzopyran

(3RS,4RS)-7-Hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylthio)octyl]-2,3-dihydro-4H-benzopyran (53mg, 0.095 mmol) was dissolved in 1,4- dioxane (1.2ml), methanol (1.2ml) and water (0.3ml). NaIO₄ (24mg, 0.11 mmol) was added dropwise thereto, and the reaction mixture was stirred for 8 hours at room temperature and then filtered. The filtrate was concentrated and the residue was subjected to column chromatography (n-hexane:ethyl acetate = 2:1) to obtain 38mg (yield: 70%) of the title compound as a colorless oil.

¹H-NMR(300MHz, CDCl₃) : δ 6.98(dd, 2H), 6.83(m, 3H), 6.33(d, 2H), 4.16(d, 1H), 2.72(m, 3H), 2.48(m, 2H), 2.16-2.11(m, 4H), 1.62(m, 2H), 1.24-0.93(m, 15H)

MS : 577(M+1)

Example 14

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfonyl)nonyl]-2,3-dihydro-4H-benzopyran

(3RS,4RS)-7-Hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-2,3-dihydro-4H-benzopyran (65mg, 0.113 mmol) was

dissolved in methanol (3mℓ) and water (1.5mℓ). Oxone (210mg, 0.34 mmol) was added dropwise thereto, and the reaction mixture was stirred for 14 hours at room temperature. After adding water, the reaction solution was extracted with ethyl acetate, dried over magnesium sulfate and then concentrated. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 4:1 →2:1) to obtain 28mg (yield: 41%) of the title compound as a colorless oil.

¹H-NMR(300MHz, CDCl₃) : δ 7.01(d, 2H), 6.83(d, 1H), 6.77(d, 2H), 6.32(s, 2H), 5.45(s, 1H), 4.95(s, 1H), 4.43(d, 1H), 4.17(d, 1H), 2.99(t, 2H), 2.90(t, 2H), 2.50(m, 1H), 2.19-2.12(m, 4H), 1.30(m, 2H), 1.28-0.99(m, 17H)
MS : 607(M+1)

Example 15

Synthesis of 4-(4-hydroxyphenyl)-4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran

Under nitrogen atmosphere, 3-bromomagnesium phenyl trimethylsilyl ether prepared from 3-bromophenyl trimethylsilyl ether (2.35g, 9.57 mmol) and magnesium turning (0.23g, 9.57 mmol) in dry tetrahydrofuran (3mℓ) was cooled to -78 °C. 7-Methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran-4-one (1g, 2.9 mmol) dissolved in dry tetrahydrofuran (2mℓ) was slowly added dropwise thereto, and the mixture was stirred for one hour. The reaction solution was quenched with saturated aqueous ammonium chloride solution and then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to remove the organic solvent. The concentrate was then subjected to column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 903mg (yield: 74%) of the title compound as a foam.

¹H-NMR(300MHz, CDCl₃) : δ 7.05(dd, 1H), 6.98(d, 2H), 6.81(d, 2H), 6.73(s, 1H), 6.67(t, 2H), 6.55(d, 3H), 5.21(s, 2H), 5.12(s, 2H), 4.71(dd, 1H), 4.21(d, 1H), 3.50(dd, 1H), 3.42(s, 6H)

Example 16**Synthesis of 4-[4-(5-chloropentyloxy)phenyl]-4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran**

4-(4-Hydroxyphenyl)-4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran (180mg, 0.4 mmol), 1-bromo-5-chloropentane (0.39ml, 2 mmol) and 2N aqueous sodium hydroxide solution (70 μ l, 2 mmol) were dissolved in acetone (4ml) and then refluxed for 6 hours. The reaction mixture was cooled to room temperature and, after adding water, extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered and then concentrated under reduced pressure to remove the organic solvent. The concentrate was subjected to column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 247mg (yield: 97%) of the title compound as a colorless oil.

¹H-NMR(300MHz, CDCl₃) : δ 7.10(m, 1H), 6.78(m, 5H), 6.70(dd, 3H), 6.63(s, 1H), 6.45(dd, 1H), 5.23(s, 2H), 5.14(s, 2H), 4.65(t, 1H), 4.22(dd, 1H), 3.83(m, 2H), 3.72(t, 2H), 3.43(s, 6H), 1.82(m, 2H), 1.48(m, 2H), 1.17(t, 2H)

Example 17**Synthesis of 4-hydroxy-4-[4-(5-iodopentyloxy)phenyl]-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran**

4-[4-(5-Chloropentyloxy)phenyl]-4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran (167mg, 0.3 mmol) and sodium iodide (139mg, 0.9 mmol) were dissolved in methyl ethyl ketone (5ml) and then refluxed for 12 hours. The reaction solution was cooled to room temperature and, after adding water, extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered and then concentrated under reduced pressure to remove the organic solvent. The concentrate was subjected to column chromatography (n-hexane:ethyl acetate =

4:1) to obtain 142mg (yield: 75%) of the title compound as a colorless oil.

¹H-NMR(300MHz, CDCl₃) : δ 7.05(m, 1H), 6.72(m, 5H), 6.65(dd, 3H), 6.55(s, 1H), 6.41(dd, 1H), 5.16(s, 2H), 5.13(s, 2H), 4.61(t, 1H), 4.21(dd, 1H), 3.81(m, 2H), 3.41(s, 6H), 3.13(t, 2H), 1.72(m, 2H), 1.56-1.45(m, 2H), 1.16(t, 2H)

Example 18

Synthesis of 4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-4-[4-(5-(4,4,5,5,5-pentafluoropentylthio)pentyl)oxy]phenyl]-2,3-dihydro-4H-benzopyran

4,4,5,5,5-Pentafluoropentylthioacetate (254mg, 1.1 mmol) was dissolved in methanol (3ml) and 2N aqueous sodium hydroxide solution (0.43ml) was added thereto. The reaction solution was stirred for one hour at room temperature and 4-hydroxy-4-[4-(5-iodopentyl)oxy]phenyl]-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran (142mg, 0.22 mmol) dissolved in methanol (2ml) was added dropwise thereto. The reaction mixture was stirred for 2 hours at 60°C and then cooled to room temperature. After adding water, the reaction solution was extracted with ethyl acetate and the organic layer was dried over anhydrous magnesium sulfate, filtered and then concentrated under reduced pressure to remove the organic solvent. The concentrate was subjected to column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 153mg (yield: 98%) of the title compound as a colorless oil.

¹H-NMR(CDCl₃, CDCl₃) : δ 7.20(t, 1H), 6.92(m, 5H), 6.78(dd, 3H), 6.63(d, 1H), 6.56(dd, 1H), 5.25(s, 2H), 5.20(s, 2H), 4.72(t, 1H), 4.20(dd, 1H), 3.80(m, 2H), 3.42(s, 6H), 2.61(m, 4H), 2.10(m, 2H), 1.72(m, 2H), 1.55(m, 4H), 1.25(s, 2H)


Example 19

Synthesis of 7-hydroxy-3-(4-hydroxyphenyl)-4-[4-(5-(4,4,5,5,5-pentafluoropentyl

-thio)pentylloxy)phenyl]-2H-benzopyran

4-Hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-4-[4-(5-(4,4,5,5,5-pentafluoropentylthio)pentylloxy)phenyl]-2,3-dihydro-4H-benzopyran (220 mg, 0.3 mmol) and pyridinium p-toluenesulfonate (789 mg, 3 mmol) were dissolved in methanol (8 ml) and then refluxed for 8 hours. The reaction solution was cooled to room temperature and, after adding water, extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered and then concentrated under reduced pressure to remove the organic solvent. The concentrate was subjected to column chromatography (n-hexane:ethyl acetate = 1:1) to obtain 142 mg (yield: 78%) of the title compound as a colorless oil.

¹H-NMR(300MHz, CDCl₃) : δ 7.12(q, 1H), 6.80(dd, 2H), 6.72(d, 1H), 6.65(dd, 2H), 6.52(dd, 3H), 6.35(d, 1H), 6.20(dd, 1H), 5.06(s, 2H), 3.76(t, 2H), 2.63(m, 4H), 2.22-2.01(m, 2H), 1.83(m, 2H), 1.75-1.62(m, 2H), 1.45-1.37(m, 2H), 1.20(m, 2H), 0.91-0.80(t, 2H)


Example 20**Synthesis of 4-methoxyphenylglyoxylic ethyl ester**

Aluminum chloride (84.30g, 632 mmol) was added to chloroform (300 ml) and chloroglyoxylic ethyl ester (60g, 439 mmol) was added dropwise to the resulting suspension over 20 minutes at 0°C. The reaction mixture was stirred for 40 minutes at 5°C. At the same temperature, anisole (68.79g, 636 mmol) was slowly added dropwise to the reaction solution and then stirred for 12 hours at 10°C. When the reaction is completed, the reaction solution was

cooled and, after adding cooling water (100mℓ), extracted with dichloromethane. The extract was dried over anhydrous magnesium sulfate and then concentrated to obtain the title compound as a yellow solid (TLC identification). The resulting compound was used in the next reaction without further purification.

Example 21

Synthesis of 4-methoxyphenylglyoxylic acid




4-Methoxyphenylglyoxylic ethyl ester obtained in Example 20 was dissolved in 20% sodium hydroxide (60mℓ) and methanol (600mℓ) and then stirred for 3 hours with heating at 80°C. When the reaction is completed, the reaction solution was extracted with diethyl ether (200mℓ) and the obtained aqueous solution was acidified (pH 1-2) with hydrochloric acid. The resulting aqueous acidic solution was extracted with dichloromethane, and the extract was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure to remove the organic solvent to obtain 34.63g (yield in two reaction steps: 43%) of the title compound as a pale violet solid.

¹H-NMR(270MHz, CDCl₃) : δ 8.59(brs, 1H, COOH), 8.44(d, ³J=8.9Hz, 2H, Ar-H), 6.99(d, ³J=8.9Hz, 2H, Ar-H), 3.92(s, 3H, OCH₃)

Example 22

Synthesis of 2-hydroxy-2-(4-methoxyphenyl)propionic acid




Methyl iodide (55mℓ, 880 mmol) was slowly added to a solution of magnesium (23g) in diethyl ether (500mℓ) at -20°C and then stirred for 3 hours at room temperature. To the resulting suspension was slowly added dropwise 4-methoxyphenylglyoxylic acid (34.6g, 192 mmol), as prepared in Example 21, dissolved in dry tetrahydrofuran (100mℓ) at 0°C , and the reaction mixture was stirred for about 12 hours at room temperature. After adding cooling water, the reaction solution was extracted with ethyl acetate and the organic layer was washed with water and saturated sodium thiosulfate solution and dried over anhydrous magnesium sulfate. The residue was concentrated under reduced pressure to remove the organic solvent to obtain 35g (yield: 93%) of the title compound as a yellow solid.

$^1\text{H-NMR}$ (270MHz, CDCl_3) : δ 7.39(d, $^3\text{J}=8.9\text{Hz}$, 2H, Ar-H), 7.16(s, 1H, COOH), 6.89(d, $^3\text{J}=8.5\text{Hz}$, 2H, Ar-H), 4.90(brs, 1H, OH), 3.80(s, 3H, OCH_3), 1.71(s, 3H, CH_3)

Example 23

Synthesis of 2-(4-methoxyphenyl)acrylic acid




2-Hydroxy-2-(4-methoxyphenyl)propionic acid (35g, 178 mmol) was dissolved in dioxane (700mℓ) and concentrated sulfuric acid (60mℓ) was added

thereto. The reaction mixture was refluxed for 2 hours under heating. The reaction solution was cooled and, after adding water, extracted with ethyl acetate. The organic layer was washed with saturated sodium thiosulfate solution and water, dried over anhydrous magnesium sulfate and then concentrated under reduced pressure to obtain 24.8g (yield: 72%) of the title compound as a brown solid.

$^1\text{H-NMR}$ (270MHz, CDCl_3) : δ 7.39(d, $^3J=8.5\text{Hz}$, 2H, Ar-H), 7.40(s, 1H, COOH), 6.89(d, $^3J=8.5\text{Hz}$, 2H, Ar-H), 6.45(s, 1H, $=\text{CH}_2$), 5.96(s, 1H, $=\text{CH}_2$), 3.82(s, 3H, OCH_3)

Example 24


Synthesis of 2-(4-methoxyphenyl)-3-(3-methoxyphenylthio)propionic acid



3-Methoxybenzenethiol(2.5ml, 20.1 mmol) was added to 2-(4-methoxyphenyl)acrylic acid (3g, 16.8 mmol) and stirred for 21 hours with heating at 125°C . The reaction solution was extracted with diethyl ether, and the ether solution was washed with 0.1N iodine-potassium iodide solution, water and saturated sodium chloride solution and dried over anhydrous magnesium sulfate. The residue was concentrated under reduced pressure to remove the organic solvent to obtain the title compound as a brown oil. The resulting compound was used in the next reaction without further purification.

Example 25

Synthesis of 7-methoxy-3-(4-methoxyphenyl)thiochroman-4-one




2-(4-Methoxyphenyl)-3-(3-methoxyphenylthio)propionic acid obtained in Example 24 was dissolved in benzene (20ml) and thionyl chloride (4.1ml, 55.9 mmol) was added thereto. The reaction mixture was heated for 2 hours at 80°C. When the reaction is completed, the reaction solution was concentrated under reduced pressure to remove benzene and cooled to 5°C. Benzene (10 ml) was added to the reaction solution and then tin(IV) chloride (4.1ml, 34.9 mmol) was slowly added dropwise thereto. The reaction mixture was stirred for 12 hours and then water (30ml), concentrated hydrochloric acid (10ml) and chloroform (30ml) were added thereto. The reaction solution was heated under refluxing for one hour and extracted with chloroform. The organic layer was washed with water and sodium hydrogen carbonate solution, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified with column chromatography (n-hexane:ethyl acetate = 8:2) to obtain 1g (yield in two reaction steps: 20%) of the title compound as a yellow solid.

¹H-NMR(270MHz, CDCl₃) : δ 8.13(d, ³J=9.5Hz, 1H, C5-H), 7.12(d, ³J=8.9Hz, 2H, Ar-H), 6.88(d, ³J=8.6Hz, 2H, Ar-H), 6.73(m, 2H, Ar-H), 4.01(dd, ³J=10.5 and 3.9Hz, 1H, C3-H), 3.85(s, 3H, OCH₃), 3.79(s, 3H, OCH₃), 3.53(dd, ³J=10.5 and 13.2Hz, 1H, C2-H), 3.31(dd, ³J=13.2 and 3.9Hz, 1H, C2-H)

Example 26

Synthesis of 7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-one




To 7-methoxy-3-(4-methoxyphenyl)thiochroman-4-one (725mg, 2.41 mmol) obtained in Example 25 was added dry tetrahydrofuran (30ml). Then lithium diisopropylamide (2.41ml, 4.83 mmol, 2.0 mol hexane/tetrahydrofuran solution) was added dropwise thereto at -78°C . The reaction mixture was stirred for 45 minutes and methyl iodide (7.5ml, 120.6 mmol) was added thereto. The reaction solution was stirred for one hour at -78°C and for 24 hours at -10°C and, after adding water, extracted with ethyl acetate. The organic layer was washed with water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue was purified with column chromatography (n-hexane: ethyl acetate = 9:1) to obtain 550mg (yield: 72%) of the title compound as a yellow solid.

$^1\text{H-NMR}$ (270MHz, CDCl_3) : δ 8.17(d, $^3\text{J}=8.9\text{Hz}$, 1H, C5-H), 7.14(dd, $^3\text{J}=8.9\text{Hz}$, $^4\text{J}=2.0\text{Hz}$, 2H, Ar-H), 6.82(dd, $^3\text{J}=8.9\text{Hz}$, 2.0Hz, 2H, Ar-H), 6.70(dd, $^3\text{J}=8.9\text{Hz}$, $^4\text{J}=2.3\text{Hz}$, 1H, C6-H), 6.57(d, $^4\text{J}=2.7\text{Hz}$, 1H, C8-H), 3.78(s, 3H, OCH_3), 3.75(s, 3H, OCH_3), 3.44(d, $^2\text{J}=4.9\text{Hz}$, 2H, $2 \times \text{C2-H}$), 1.58(s, 3H, C3- CH_3)

Example 27

Synthesis of 4-[9-(t-butyldimethylsilyloxy)-1-nonynyl]-4-hydroxy-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman




To 9-(t-butyldimethylsilyloxy)-1-nonyne (2.23g, 8.75 mmol) was added dry tetrahydrofuran (30ml). Then n-butyl lithium (4.65ml, 7.87 mol, 1.69 mol/l tetrahydrofuran solution) was added dropwise thereto at -78°C and the resulting mixture was stirred for one hour at -20°C . At the same temperature, to the reaction solution was added 7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-one (550mg, 1.75 mmol), as obtained in Example 26, dissolved in tetrahydrofuran (20ml), and then the mixture was stirred for 24 hours at -10°C . When the reaction is completed, saturated ammonium chloride solution was added to the reaction solution which was then extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified with column chromatography (n-hexane:ethyl acetate = 9:1) to obtain 946mg (yield: 95%) of the title compound as a white solid.

$^1\text{H-NMR}$ (270MHz, CDCl_3) : δ 7.86(d, $^3\text{J}=8.5\text{Hz}$, 1H, Ar-H), 7.59(d, $^3\text{J}=8.9\text{Hz}$, 2H, Ar-H), 6.87(d, $^3\text{J}=8.9\text{Hz}$, 2H, Ar-H), 6.63(m, 2H, Ar-H), 4.25(d, $^2\text{J}=12.6\text{Hz}$, 1H, C2-H), 3.81(s, 3H, OCH_3), 3.77(s, 3H, OCH_3), 3.59(t, $^3\text{J}=6.6\text{Hz}$, 2H, $\text{CH}_2\text{-OTBS}$), 2.70(d, $^2\text{J}=12.6\text{Hz}$, 1H, C2-H), 2.18(t, $^2\text{J}=6.6\text{Hz}$, 3H, $\text{CH}_2\text{-C}\equiv\text{C}$ and OH), 1.48(s, 3H, C3- CH_3), 1.36(m, 10H, alkyl-H), 0.89(s, 9H, t-butyl-H), 0.04(s, 6H, $2 \times \text{CH}_3$)

Example 28

Synthesis of 4-[9-(t-butyldimethylsilyloxy)-1-nonynyl]-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman




Dichloromethane (30ml) was added to 4-[9-(t-butyldimethylsilyloxy)-1-

nonyl]-4-hydroxy-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman (946mg, 1.66 mmol) obtained in Example 27, and then zinc iodide (795mg, 2.49 mmol) and sodium cyanoborohydride (782mg, 12.45 mmol) were added thereto. The reaction solution was stirred for 24 hours at room temperature and, after adding water, extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified with column chromatography (n-hexane:ethyl acetate = 9:1) to obtain 569mg (yield: 62%, 3RS,4RS/3RS,4SR=5:1) of the title compound as a white solid.

¹H-NMR(270MHz, CDCl₃, 3RS,4RS-compound) : δ 7.25(m, 3H, Ar-H), 6.82(d, ³J=8.9Hz, 2H, Ar-H), 6.68(m, 2H, Ar-H), 3.78(s, 3H, OCH₃), 3.76(s, 3H, OCH₃), 3.72(s, 1H, C4-H), 3.76(d, ²J=12.2Hz, 1H, C2-H), 3.58(t, ³J=6.6Hz, 2H, CH₂-OTBS), 2.99(d, ²J=12.2Hz, 1H, C2-H), 2.02(m, 2H, CH₂-C≡C), 1.44(s, 3H, C3-CH₃), 1.20(m, 10H, alkyl-H), 0.89(s, 9H, t-butyl-H), 0.05(s, 6H, 2×CH₃)

Example 29

Synthesis of 4-[9-(t-butyl dimethylsilyloxy)nonyl]-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman




Methanol (60ml) and 10% Pd/C (500mg) were added to 4-[9-(t-butyl dimethylsilyloxy)-1-nonyl]-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman (560mg, 1.01 mmol) obtained in Example 28, and the mixture was stirred for 2 days under hydrogen gas (normal pressure). Ethyl acetate was added to the reaction solution which was then filtered, washed several times with ethyl

acetate and concentrated under reduced pressure to remove the organic solvent. To the residue were added methanol (60ml) and 10% Pd/C (300mg), and the reaction mixture was stirred for 8 hours at 5 atmosphere under hydrogen gas. Ethyl acetate was added again to the reaction solution which was then filtered and concentrated under reduced pressure to obtain 450mg (yield: 80%) of the title compound as an oil. The resulting compound was used in the next reaction without further purification.

$^1\text{H-NMR}$ (270MHz, CDCl_3 , 3RS,4RS-compound) : δ 7.28(d, $^3\text{J}=8.9\text{Hz}$, 2H, Ar-H), 6.91(m, 3H, Ar-H), 6.72(d, $^4\text{J}=2.3\text{Hz}$, 1H, C8-H), 6.58(dd, $^3\text{J}=8.6\text{Hz}$, $^4\text{J}=2.6\text{Hz}$, 1H, Ar-H), 3.82(s, 3H, OCH_3), 3.78(s, 3H, OCH_3), 3.64(d, $^2\text{J}=11.5\text{Hz}$, 1H, C2-H), 3.56(t, $^3\text{J}=6.6\text{Hz}$, 2H, $\text{CH}_2\text{-OTBS}$), 2.98(d, $^2\text{J}=11.5\text{Hz}$, 1H, C2-H), 2.71(brt, 1H, C4-H), 1.48-1.17(m, 19H, C3- CH_3 and alkyl-H), 0.88(s, 9H, t-butyl-H), 0.03(s, 6H, $2\times\text{CH}_3$)

Example 30

Synthesis of 4-(9-hydroxynonyl)-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman




4-[9-(t-Butyldimethylsilyloxy)nonyl]-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman (400mg, 0.72 mmol) obtained in Example 29 was dissolved in tetrahydrofuran (40ml), and 3N-HCl (2ml) was added thereto. The reaction mixture was stirred for 3 hours at room temperature. When the reaction is completed, water was added to the reaction solution which was then extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified with

column chromatography (n-hexane:ethyl acetate = 7:3) to obtain 235mg (yield: 74%, 3RS,4RS/3RS,4SR=9:1) of the title compound as a white solid.

$^1\text{H-NMR}$ (270MHz, CDCl_3 , 3RS,4RS-compound) : δ 7.29(d, $^3\text{J}=8.9\text{Hz}$, 2H, Ar-H), 6.91(m, 3H, Ar-H), 6.71(m, 1H, Ar-H), 6.58(m, 1H, Ar-H), 3.82(s, 3H, OCH_3), 3.78(s, 3H, OCH_3), 3.68(m, 4H, $\text{CH}_2\text{-OH}$, C2-H), 2.98(d, $^2\text{J}=11.6\text{Hz}$, 1H, C2-H), 2.78(brt, 1H, C4-H), 1.56-1.08(m, 19H, C3- CH_3 and alkyl-H)

Example 31

Synthesis of 4-(9-methanesulfonyloxynonyl)-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman




4-(9-Hydroxynonyl)-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman (131mg, 0.30 mmol) obtained in Example 30 was dissolved in dichloromethane (12mℓ) and then triethylamine (0.2mℓ, 1.48 mmol) and methanesulfonyl chloride (0.11mℓ, 1.48 mmol) were added thereto. The reaction mixture was stirred for 40 minutes at room temperature. When the reaction is completed, water was added to the reaction solution which was then extracted with ethyl acetate. The organic layer was washed with water and saturated sodium chloride solution and dried over anhydrous magnesium sulfate. The residue was purified with column chromatography (n-hexane:ethyl acetate = 7:3) to obtain 141mg (yield: 91%, 3RS,4RS/3RS,4SR= 8.5/1) of the title compound as an oil.

$^1\text{H-NMR}$ (270MHz, CDCl_3 , 3RS,4RS-compound) : δ 7.29(d, $^3\text{J}=8.9\text{Hz}$, 2H, Ar-H), 6.91(m, 3H, Ar-H), 6.70(d, $^4\text{J}=2.3\text{Hz}$, 1H, C8-H), 6.58(dd,

$^3J=8.5\text{Hz}$, $^4J=2.3\text{Hz}$, 1H, Ar-H), 4.18(t, $^3J=6.6\text{Hz}$, 2H, OCH_2), 3.82(s, 3H, OCH_3), 3.78(s, 3H, OCH_3), 3.64(d, $^2J=11.3\text{Hz}$, 1H, C2-H), 2.99(s, 3H, OSO_2CH_3), 2.97(brd, $^2J=\text{not resolved}$, 1H, C2-H), 2.78(brt, 1H, C4+1), 1.63(m, 3H, alkyl-H), 1.37-1.08(m, 16H, $\text{C}_3\text{-CH}_3$ and alkyl-H)

Example 32

Synthesis of 7-methoxy-3-(4-methoxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-thiochroman




4,4,5,5,5-Pentafluoropentylthioacetate (424mg, 1.89 mmol) was dissolved in absolute methanol (10mℓ) and 1M sodium methoxide (1.62mℓ) was added thereto. The reaction solution was stirred for one hour at room temperature and 4-(9-methanesulfonyloxynonyl)-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman (141mg, 0.27 mmol), as obtained in Example 31, dissolved in dry tetrahydrofuran (10mℓ) was added dropwise thereto at room temperature. The reaction mixture was stirred for 24 hours. When the reaction is completed, water was added to the reaction solution which was then extracted with ethyl acetate. The organic layer was washed with water and saturated sodium chloride solution and dried over anhydrous magnesium sulfate. The residue was concentrated under reduced pressure to remove the organic solvent and then purified with column chromatography (n-hexane:ethyl acetate = 9:1) to obtain 164mg (yield: 98%, 3RS,4RS/3RS,4SR=8.5/1) of the title compound as a yellow oil.

$^1\text{H-NMR}$ (270MHz, CDCl_3 , 3RS,4RS-compound) : δ 7.29(d, $^3J=8.9\text{Hz}$, 2H, Ar-H), 6.90(m, 3H, Ar-H), 6.72(d, $^4J=2.7\text{Hz}$, 1H, C8-H), 6.58(dd,

$^3J=8.6\text{Hz}$, $^4J=2.7\text{Hz}$, 1H, Ar-H), 3.83(d, $^2J=11.9\text{Hz}$, 1H, C2-H), 3.82(s, 3H, OCH₃), 3.78(s, 3H, OCH₃), 2.98(d, $^2J=11.9\text{Hz}$, 1H, C2-H), 2.74(brt, 1H, C4-H), 2.57(t, $^3J=6.9\text{Hz}$, 2H, S-CH₂), 2.47(t, $^3J=6.9\text{Hz}$, 2H, S-CH₂), 2.13(m, 2H, alkyl-H), 1.88(m, 2H, alkyl-H), 1.50-1.08(m, 19H, C3-CH₃ and alkyl-H)

Example 33

Synthesis of (3RS,4RS)- and (3RS,4SR)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman



7-Methoxy-3-(4-methoxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-thiochroman (164mg, 0.26 mmol) obtained in Example 32 was dissolved in dichloromethane (18ml) and boron tribromide (1.85ml, 1.0 mol/l dichloromethane solution) was added thereto at -78°C . The reaction mixture was stirred for one hour at the same temperature and for about 10 hours at room temperature. When the reaction is completed, water was added to the reaction solution which was then extracted with ethyl acetate. The organic layer was washed with sodium hydrogen sulfite solution and water and dried over anhydrous magnesium sulfate. The residue was concentrated under reduced pressure to remove the organic solvent and then purified with column chromatography (n-hexane:ethyl acetate = 8:2) to obtain 109mg (yield: 70%) of the title 3RS,4RS-compound and 9mg (yield: 6%) of the 3RS,4SR-compound as a white solid.


$^1\text{H-NMR}$ (270MHz, CDCl_3 , 3RS,4RS-compound) : δ 7.25(d, $^3J=8.6\text{Hz}$, 2H, Ar-H), 6.85(dd, $^3J=8.6$ and 8.2Hz , 3H, Ar-H), 6.67(d, $^4J=2.6\text{Hz}$, 1H, C8-H), 6.50(dd, $^3J=8.3\text{Hz}$, $^4J=2.3\text{Hz}$, 1H, Ar-H), 4.94(brs, 1H, OH), 4.75(brs,

1H, OH), 3.62(d, $^2J=11.6\text{Hz}$, 1H, C2-H), 2.96(d, $^2J=11.6\text{Hz}$, 1H, C2-H), 2.69(brt, 1H, C4-H), 2.58(t, $^3J=6.9\text{Hz}$, 2H, S-CH₂), 2.48(t, $^3J=6.9\text{Hz}$, 2H, S-CH₂), 2.12(m, 2H, alkyl-H), 1.88(m, 2H, alkyl-H), 1.69-1.07(m, 19H, C3-CH₃ and alkyl-H)

$^1\text{H-NMR}$ (270MHz, CDCl₃, 3RS,4SR-compound) : δ 7.24(d, $^3J=8.6\text{Hz}$, 2H, Ar-H), 6.65(m, 3H, Ar-H), 6.48(d, $^4J=2.4\text{Hz}$, 1H, Ar-H), 6.31(dd, $^3J=8.3\text{Hz}$, $^4J=2.3\text{Hz}$, 1H, Ar-H), 4.54(brs, 1H, OH), 4.46(brs, 1H, OH), 3.21(2 $\times$ d, 2J =not resolved, 2H, 2 $\times$ C2-H), 2.85(brt, 1H, C4-H), 2.58(t, $^3J=6.9\text{Hz}$, 2H, S-CH₂), 2.50(t, $^3J=6.9\text{Hz}$, 2H, S-CH₂), 2.16(m, 2H, alkyl-H), 1.87(m, 2H, alkyl-H), 1.63-1.16(m, 19H, C3-CH₃ and alkyl-H)

Example 34

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman




Methanol (16mL) and water (4mL) were added to the mixture of (3RS, 4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)-nonyl]thiochroman (85mg, 0.14 mmol) obtained in Example 33 and NaIO₄ (34 mg, 0.16 mmol), and the reaction mixture was stirred for 3.5 hours at room temperature. Water was added to the reaction solution which was then extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and then purified with preparative TLC (n-hexane:ethyl acetate = 1:1) to obtain 39mg (yield: 45%) of the title compound as a white solid. In this reaction, 13mg (15%) of the unreacted starting 3RS,4RS-compound was recovered.

$^1\text{H-NMR}$ (270MHz, CD_3OD) : δ 7.21(d, $^3\text{J}=8.6\text{Hz}$, 2H, Ar-H), 6.81(d, $^3\text{J}=8.3\text{Hz}$, 1H, C5-H), 6.73(d, $^3\text{J}=8.6\text{Hz}$, 2H, Ar-H), 6.51(d, $^4\text{J}=2.3\text{Hz}$, 1H, C8-H), 6.39(dd, $^3\text{J}=8.3\text{Hz}$, $^4\text{J}=2.3\text{Hz}$, 1H, C6-H), 3.57(d, $^2\text{J}=11.5\text{Hz}$, 1H, C2-H), 3.26(d, $^2\text{J}=11.5\text{Hz}$, 1H, C2-H), 2.80(m, 4H, $2 \times \text{S(O)-CH}_2$), 2.27(m, 2H, alkyl-H), 2.04(m, 2H, alkyl-H), 1.67(m, 2H, alkyl-H), 1.54-1.02(m, 17H, C3-CH_3 and alkyl-H)

Example 35


Synthesis of (3RS,4RS)-4-hydroxy-4-(3-hydroxyphenyl)-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran



Under argon atmosphere 3-bromomagnesium phenyl trimethylsilyl ether was prepared from 3-bromophenyl trimethylsilyl ether (3g, 12.24 mmol) and magnesium turning (300mg, 12.34 mmol) in dry tetrahydrofuran (10ml) and cooled to 0°C . 7-Methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran-4-one (900mg, 2.51 mmol) dissolved in dry tetrahydrofuran (5ml) was slowly added dropwise thereto and then refluxed for 12 hours. The reaction mixture was cooled to room temperature, quenched with water and then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to remove the organic solvent. The concentrate was separated by column chromatography (n-hexane:ethyl acetate = 2:1) to obtain 760mg (yield: 67%) of the title compound as a foam.

Example 36

Synthesis of (3RS,4RS)-4-(3-hydroxyphenyl)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran




(3RS,4RS)-4-Hydroxy-4-(3-hydroxyphenyl)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran (1.19g, 2.63 mmol) prepared in Example 35 was dissolved in methanol (50mℓ), and 10% Pd/C (200 mg) was slowly added dropwise thereto. The reaction mixture was stirred under hydrogen atmosphere for 12 hours and then filtered. The filtrate was concentrated under reduced pressure to remove the organic solvent. The concentrate was separated by column chromatography (n-hexane:ethyl acetate = 8:1) to obtain 594mg (yield: 50%) of the title compound as a colorless foam.

¹H-NMR(300MHz, CDCl₃) : δ 7.17(s, 1H), 6.81(d, 2H), 6.76(s, 1H), 6.71(d, 2H), 6.59(s, 1H), 6.47(d, 1H), 6.41(m, 1H), 6.08(d, 1H), 5.92(s, 1H), 5.30(s, 1H), 5.08(s, 2H), 5.05(s, 2H), 4.53(d, 1H), 3.94(d, 1H), 3.81(s, 1H), 3.39(s, 3H), 3.36(s, 3H), 1.42(s, 3H)

Example 37

Synthesis of (3RS,4RS)-4-[3-(4-chlorobutyloxy)phenyl]-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran




(3RS,4RS)-4-(3-Hydroxyphenyl)-7-methoxymethyloxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran (260mg, 0.59 mmol), 1-bromo-4-chlorobutane (0.8ml, 2.98 mmol) and aqueous 2N-NaOH solution (0.8ml) were dissolved in acetone (10ml) and then stirred for 4 hours at 50°C. The reaction mixture was cooled to room temperature and then water was added thereto. The reaction solution was extracted with ethyl acetate and the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to remove the organic solvent. The concentrate was separated by column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 300mg (yield: 96%) of the title compound as a colorless oil.

¹H-NMR(300MHz, CDCl₃) : δ 7.17(d, 1H), 6.79(d, 2H), 6.70(d, 2H), 6.69(s, 1H), 6.59(s, 1H), 6.45(m, 2H), 6.15(d, 1H), 5.98(s, 1H), 5.06(s, 2H), 5.01(s, 2H), 4.53(d, 1H), 3.96(d, 1H), 3.84(s, 1H), 3.60-3.47(m, 4H), 3.41(s, 3H), 3.35(s, 3H), 1.9-1.7(m, 4H), 1.42(s, 3H)

Example 38

Synthesis of (3RS,4RS)-4-[3-(4-iodobutyloxy)phenyl]-7-methoxymethyloxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran




(3RS,4RS)-4-[3-(4-Chlorobutyloxy)phenyl]-7-methoxymethyloxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran (300mg, 0.57 mmol) and sodium iodide (260mg, 1.73 mmol) were dissolved in methyl ethyl ketone (30ml) and then refluxed for 12 hours. The reaction mixture was cooled to room temperature and then water was added thereto. The reaction solution

was extracted with ethyl acetate and the organic layer was dried over anhydrous magnesium sulfate, filtered and then concentrated under reduced pressure to remove the organic solvent. The concentrate was separated by column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 340mg (yield: 97%) of the title compound as a colorless oil.

$^1\text{H-NMR}$ (300MHz, CDCl_3) : δ 7.17(d, 1H), 6.79(d, 2H), 6.70(d, 2H), 6.69(s, 1H), 6.59(s, 1H), 6.45(m, 2H), 6.15(d, 1H), 5.98(s, 1H), 5.06(s, 2H), 5.01(s, 2H), 4.53(d, 1H), 3.96(d, 1H), 3.84(s, 1H), 3.60-3.45(m, 2H), 3.41(s, 3H), 3.35(s, 3H), 3.13(t, 2H), 1.9-1.7(m, 4H), 1.42(s, 3H)

Example 39

Synthesis of (3RS,4RS)-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylthio)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran




4,4,5,5,5-Pentafluoropentylthioacetate (650mg, 2.75 mmol) was dissolved in methanol (2ml) and aqueous 2N-NaOH solution (1.4ml) was added thereto. The mixture was stirred for one hour at room temperature. (3RS,4RS)-4-[3-(4-Iodobutyloxy)phenyl]-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran (340mg, 0.55 mmol) dissolved in methanol (10ml) was added dropwise thereto and then stirred for 12 hours at 60°C. The reaction mixture was cooled to room temperature and then water was added thereto. The reaction solution was extracted with ethyl acetate and the organic layer was dried over anhydrous magnesium sulfate, filtered and

concentrated under reduced pressure to remove the organic solvent. The concentrate was separated by column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 346mg (yield: 92%) of the title compound as a colorless oil.

$^1\text{H-NMR}$ (300MHz, CDCl_3) : δ 7.18(d, 1H), 6.80(d, 2H), 6.71(d, 2H), 6.70(s, 1H), 6.60(s, 1H), 6.46(m, 2H), 6.16(d, 1H), 6.00(s, 1H), 5.07(s, 2H), 5.02(s, 2H), 4.54(d, 1H), 3.97(d, 1H), 3.85(s, 1H), 3.60-3.45(m, 2H), 3.42(s, 3H), 3.36(s, 3H), 2.5(m, 4H), 2.1(m, 2H), 1.81(m, 2H), 1.67(m, 4H), 1.43(s, 3H)

Example 40

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylthio)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran




(3RS,4RS)-7-Methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylthio)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran (274mg, 0.4 mmol) and pyridinium p-toluenesulfonate (508mg, 2.02 mmol) were dissolved in methanol (10ml) and then refluxed for 14 hours. The reaction mixture was cooled to room temperature and then water was added thereto. The reaction solution was extracted with ethyl acetate and the organic layer was washed with water, dried over anhydrous magnesium sulfate and then concentrated. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 167mg (yield: 75%) of the title compound as a white foam.

$^1\text{H-NMR}$ (300MHz, CDCl_3) : δ 6.83(m, 1H), 6.74(d, 2H), 6.65(d, 1H), 6.53(d, 2H), 6.5(m, 1H), 6.39(s, 1H), 6.27(m, 1H), 6.19(d, 1H), 5.96(s, 1H), 5.29(s, 1H), 5.22(s, 1H), 4.52(d, 1H), 3.95(d, 1H), 3.81(s, 1H), 3.6(m, 2H), 2.49(m, 4H), 2.1(m, 2H), 1.82(m, 2H), 1.65(m, 4H), 1.42(s, 3H)

Example 41

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylsulfinyl)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran




(3RS,4RS)-7-Hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylthio)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran (72mg, 0.12 mmol) was dissolved in methanol (5ml) and water (1ml), and NaIO_4 (35mg, 0.16 mmol) was added thereto. The reaction solution was stirred for 12 hours at room temperature and then extracted with ethyl acetate. The organic layer thus separated was washed with water, dried over anhydrous magnesium sulfate and then concentrated. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 2:1) to obtain 66mg (yield: 89%) of the title compound as a white foam.

$^1\text{H-NMR}$ (300MHz, CDCl_3) : δ 6.91(t, 1H), 6.72(s, 1H), 6.67(s, 1H), 6.58(d, 2H), 6.47(d, 1H), 6.41(s, 1H), 6.28(d, 2H), 6.17(s, 1H), 5.78(d, 1H), 4.45(m, 1H), 4.06(m, 1H), 3.78(s, 1H), 3.6(m, 1H), 3.45(m, 1H), 2.7(m, 4H), 2.2(m, 4H), 1.7(m, 4H), 1.42(s, 3H)

Example 42

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylsulfonyl)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran




(3RS,4RS)-7-Hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylthio)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran (95mg, 0.16 mmol) was dissolved in methanol (5ml) and water (2ml), and oxone (147mg, 0.24 mmol) was added thereto. The reaction solution was stirred for 4 hours at room temperature and then extracted with ethyl acetate. The organic layer thus separated was washed with water, dried over anhydrous magnesium sulfate and then concentrated. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 2:1) to obtain 77mg (yield: 77%) of the title compound as a white foam.

¹H-NMR(300MHz, CDCl₃) : δ 7.01(t, 1H), 6.83(d, 1H), 6.76(d, 2H), 6.67(d, 2H), 6.6(d, 1H), 6.50(s, 1H), 6.38(d, 2H), 6.14(s, 1H), 5.90(s, 1H), 5.11(s, 1H), 4.58(d, 1H), 4.03(d, 1H), 3.90(s, 1H), 3.6(m, 2H), 3.12(m, 4H), 2.27(m, 4H), 2.08(m, 2H), 1.82(m, 2H), 1.53(s, 3H)

Example 43

Synthesis of thioacetic acid 2-piperidinoethyl ester




Potassium thioacetate (1.8g, 16.35 mmol) was added to acetone (50ml)

and then stirred for 10 minutes under argon atmosphere. 1-(2-Chloroethyl)-piperidine (1.61g, 10.40 mmol) was added dropwise thereto and stirred for 18 hours under argon atmosphere at room temperature. After adding water, the reaction solution was extracted with ethyl acetate. The organic layer thus separated was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue was purified with flash column chromatography (dichloromethane:ethyl acetate = 19:1) to obtain 0.71g (yield: 35%) of the title compound as a red oil.

$^1\text{H-NMR}(\text{CDCl}_3)$: δ 3.04(t, $J=8\text{Hz}$, 2H), 2.52(t, $J=6\text{Hz}$, 2H), 2.45(t, $J=5\text{Hz}$, 4H), 2.34(s, 3H), 1.60(m, 4H), 1.44(m, 2H)

Example 44

Synthesis of (3RS,4RS)-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-4-[9-(2-piperidinoethylthio)nonyl]-2,3-dihydro-4H-benzopyran




Thioacetic acid 2-piperidinoethyl ester (241mg, 1.29 mmol) was dissolved in methanol (10ml) and aqueous 2N-NaOH solution (1.5ml) was added thereto. The mixture was stirred for one hour at room temperature. To the resulting solution was added (3RS,4RS)-3-[4-(methoxymethoxy)phenyl]-3-methyl-4-[9-(p-toluenesulfonyloxy)nonyl]-2,3-dihydro-4H-benzopyran (274mg, 0.43 mmol) dissolved in methanol (10ml). The reaction mixture was stirred for 2 hours at 60°C and then cooled to room temperature. After adding water, the reaction solution was extracted with ethyl acetate. The organic layer thus separated was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue was purified with flash

column chromatography (n-hexane:ethyl acetate = 8:1 → dichloromethane:ethyl acetate = 19:1 → dichloromethane:ethanol = 9:1) to obtain 187mg (yield: 70%) of the title compound as a pale yellow oil.

$^1\text{H-NMR}$ (300MHz, CDCl_3) : δ 7.07(d, $J=7\text{Hz}$, 2H), 6.95(d, $J=9\text{Hz}$, 2H), 6.88(d, $J=9\text{Hz}$, 1H), 6.50(m, 2H), 5.11(s, 2H), 5.07(s, 2H), 4.45(d, $J=10\text{Hz}$, 1H), 4.20(d, $J=2\text{Hz}$, 1H), 3.42(s, 6H), 2.57(m, 3H), 2.50(m, 2H), 2.44(m, 3H), 2.39(m, 4H), 1.53(m, 6H), 1.38(d, $J=5\text{Hz}$, 2H), 1.30-1.05(m, 16H)

Example 45

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(2-piperidinoethylthio)nonyl]-2,3-dihydro-4H-benzopyran




(3RS,4RS)-7-Methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-4-[9-(2-piperidinoethylthio)nonyl]-2,3-dihydro-4H-benzopyran (174mg, 0.28 mmol) and methanol solution of 5N-HCl (1mℓ) were dissolved in methanol (10mℓ) and then stirred for 5 hours at 40°C. The reaction solution was cooled to room temperature and, after adding water, extracted with ethyl acetate. The organic layer thus separated was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue was purified with flash column chromatography (dichloromethane:ethanol = 9:1) to obtain 139mg (yield: 93%) of the title compound as a pale yellow oil.

$^1\text{H-NMR}$ (300MHz, CDCl_3) : δ 6.99(dd, $J=9\text{Hz}$, $J=2\text{Hz}$, 2H), 6.82(d, $J=9\text{Hz}$, 1H), 6.73(d, $J=9\text{Hz}$, 2H), 6.28(m, 2H), 4.43(d, $J=10\text{Hz}$, 1H), 4.17(d, $J=2\text{Hz}$, 1H), 2.85(m, 1H), 2.61(m, 3H), 2.53(m, 4H), 2.42(t, $J=9\text{Hz}$, 3H),

1.63(m, 5H), 1.41(m, 4H), 1.22-1.03(m, 16H)

Example 46

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-((2-piperidinoethyl)sulfinyl)nonyl]-2,3-dihydro-4H-benzopyran




(3RS,4RS)-7-Hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(2-piperidinoethyl-thio)nonyl]-2,3-dihydro-4H-benzopyran (126mg, 0.24 mmol) was dissolved in methanol (5mℓ) and water (1.2mℓ), and NaIO₄ (62mg, 0.29 mmol) was added thereto. The reaction solution was stirred for 4 hours at room temperature and then filtered. The filtrate was concentrated and the residue was purified with flash column chromatography (dichloromethane:ethanol = 13:1 → 10:1) to obtain 96mg (yield: 74%) of the title compound as a white foamy solid.

¹H-NMR(300MHz, CD₃OD) : δ 6.98(d, J=9Hz, 2H), 6.76(d, J=8Hz, 1H), 6.69(d, J=9Hz, 2H), 6.23(dd, J=8Hz, J=2Hz, 1H), 6.15(d, J=2Hz, 1H), 4.43(d, J=10Hz, 1H), 4.15(d, J=7Hz, 1H), 2.92-2.61(m, 6H), 2.51(d, J=2Hz, 1H), 2.47(m, 4H), 1.63(m, 2H), 1.51(m, 5H), 1.36(m, 4H), 1.22-1.05(m, 14H)

MS : 542(M+1)⁺

Example 47


Synthesis of 4-(3-hydroxyphenyl)-4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran



Under nitrogen atmosphere 3-bromomagnesium phenyl trimethylsilyl ether was prepared from 3-bromophenyl trimethylsilyl ether (629mg, 2.1 mmol) and magnesium turning (52mg, 2.1 mmol) in dry tetrahydrofuran (1.5mℓ) and then cooled to -78°C . 7-Methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-2,3-dihydro-benzopyran-4-one (250mg, 0.7 mmol) dissolved in dry tetrahydrofuran (2mℓ) was slowly added dropwise thereto and then stirred for one hour. The reaction solution was quenched with saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to remove the organic solvent. The concentrate was separated by column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 283mg (yield: 92%) of the title compound as a foam.

Example 48


Synthesis of 4-[3-(5-chloropentyloxy)phenyl]-4-hydroxy-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-2,3-dihydro-4H-benzopyran



4-(3-Hydroxyphenyl)-4-hydroxy-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-2,3-dihydro-4H-benzopyran (283mg, 0.6 mmol), 1-bromo-5-chloropentane (598mg, 3.2 mmol) and aqueous 2N-NaOH solution (1ml) were dissolved in acetone (3ml) and then refluxed for 6 hours. The reaction mixture was cooled to room temperature and then water was added thereto. The reaction solution was extracted with ethyl acetate and the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to remove the organic solvent. The concentrate was separated by column chromatography (n-hexane:ethyl acetate = 8:1) to obtain 307mg (yield: 94%) of the title compound as a colorless oil.

Example 49

Synthesis of 4-[3-(5-chloropentyloxy)phenyl]-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-2,3-dihydro-4H-benzopyran




4-[3-(5-Chloropentyloxy)phenyl]-4-hydroxy-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-2,3-dihydro-4H-benzopyran (307mg, 0.56 mmol) was dissolved in methanol (15ml), and 10% Pd/C (102mg) was slowly added dropwise thereto. Then the reaction mixture was stirred under hydrogen atmosphere for 2 hours and filtered. The filtrate was concentrated under reduced pressure to remove the organic solvent. The concentrate was separated by column chromatography (n-hexane:ethyl acetate = 8:1) to obtain 283mg (yield: 95%, 3RS,4RS/3RS,4SR=1:1) of the title compound as a colorless oil.

¹H-NMR(300MHz, CDCl₃, 3RS,4RS-compound) : δ 7.10(m, 1H), 6.78(m, 5H), 6.70(t, 3H), 6.63(s, 1H), 6.45(d, 1H), 5.90(s, 1H), 5.15(d, 4H), 4.61(dd, 1H), 4.20(dd, 1H), 3.83(t, 2H), 3.42(s, 3H), 3.21(s, 3H), 1.80-1.17(m, 6H)

Example 50


Synthesis of 4-[3-(5-iodopentyloxy)phenyl]-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-2,3-dihydro-4H-benzopyran



4-[3-(5-Chloropentyloxy)phenyl]-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-2,3-dihydro-4H-benzopyran (283mg, 0.5 mmol) and sodium iodide (24mg, 1.6 mmol) were dissolved in methyl ethyl ketone (5ml) and then refluxed for 12 hours. The reaction mixture was cooled to room temperature and then water was added thereto. The reaction solution was extracted with ethyl acetate and the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to remove the organic solvent. The concentrate was separated by column chromatography (n-hexane:ethyl acetate = 8:1) to obtain 293mg (yield: 94%) of the title compound as a yellow oil.

Example 51


Synthesis of 7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-4-[3-(5-(4,4,5,5,5-pentafluoropentylthio)pentyloxy)phenyl]-2,3-dihydro-4H-benzopyran



4,4,5,5,5-Pentafluoropentylthioacetate (537mg, 2.3 mmol) was dissolved in methanol (5ml) and aqueous 2N-NaOH solution (0.5ml) was added thereto. The mixture was stirred for one hour at room temperature. 4-[3-(5-Iodopentyl)oxyphenyl]-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-2,3-dihydro-4H-benzopyran (293mg, 0.47 mmol) dissolved in methanol (2ml) was added dropwise thereto and then stirred for 2 hours at 60 °C. The reaction mixture was cooled to room temperature and then water was added thereto. The reaction solution was extracted with ethyl acetate and the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to remove the organic solvent. The concentrate was separated by column chromatography (n-hexane:ethyl acetate = 8:1) to obtain 290mg (yield: 89%) of the title compound as a colorless oil.

Example 52


Synthesis of 7-hydroxy-3-(4-hydroxyphenyl)-4-[3-(5-(4,4,5,5,5-pentafluoropentylthio)pentyl)oxyphenyl]-2,3-dihydro-4H-benzopyran



7-Methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-4-[3-(5-(4,4,5,5,5-pentafluoropentylthio)pentyl)oxy]phenyl]-2,3-dihydro-4H-benzopyran (290mg, 0.4 mmol) and pyridinium p-toluenesulfonate (1.05g, 4 mmol) were dissolved in methanol (6ml) and then refluxed for 8 hours. The reaction mixture was cooled to room temperature and then water was added thereto. The reaction solution was extracted with ethyl acetate and the organic layer was dried over anhydrous magnesium sulfate, filtered and then concentrated under reduced pressure to remove the organic solvent. The concentrate was separated by column chromatography (n-hexane:ethyl acetate = 1:1) to obtain 177mg (yield: 74%) of the title compound as a colorless oil.

Example 53

Synthesis of 7-hydroxy-3-(4-hydroxyphenyl)-4-[3-(5-(4,4,5,5,5-pentafluoropentyl-sulfinyl)pentyl)oxy]phenyl]-2,3-dihydro-4H-benzopyran




7-Hydroxy-3-(4-hydroxyphenyl)-4-[3-(5-(4,4,5,5,5-pentafluoropentylthio)pentyl)oxy]phenyl]-2,3-dihydro-4H-benzopyran (90mg, 0.15 mmol) was dissolved in

1,4-dioxane (1.5ml), methanol (1.5ml) and water (0.38ml), and NaIO₄ (35.5mg, 0.16 mmol) was added dropwise thereto. The reaction solution was stirred for 8 hours at room temperature and then filtered. The filtrate was concentrated and the residue was separated by column chromatography (n-hexane:ethyl acetate = 1:1) to obtain 58mg (yield: 63%, 3RS,4RS/3RS,4SR= 1:1) of the title compound as a colorless oil.

¹H-NMR(300MHz, CDCl₃, 3RS,4RS-compound) : δ 8.36(s, 1H), 7.20(dd, 1H), 6.90(d, 1H), 6.80(t, 3H), 6.52(t, 2H), 6.40(s, 1H), 6.36(m, 2H), 5.83(s, 1H), 5.15(s, 1H), 4.43(dd, 1H), 4.25(dd, 2H), 3.80-3.40(dd, 2H), 3.22-2.70(m, 4H), 2.52-2.22(m, 4H), 2.0-1.43(m, 6H)

Example 54

Synthesis of 7-hydroxy-3-(4-hydroxyphenyl)-4-[3-(5-(4,4,5,5,5-pentafluoropentyl-sulfonyl)pentyloxy)phenyl]-2,3-dihydro-4H-benzopyran




7-Hydroxy-3-(4-hydroxyphenyl)-4-[3-(5-(4,4,5,5,5-pentafluoropentylthio)pentyloxy)phenyl]-2,3-dihydro-4H-benzopyran (84mg, 0.14 mmol) was dissolved in methanol (4ml) and water (2ml), and oxone (262mg, 0.4 mmol) was added dropwise thereto. The reaction solution was stirred for 1.5 hours at room temperature and, after adding water, extracted with ethyl acetate. The organic layer thus separated was dried over anhydrous magnesium sulfate, filtered and then concentrated under reduced pressure to remove the organic solvent. The residue was separated by column chromatography (n-hexane:ethyl acetate = 5:1)

to obtain 36mg (yield: 40%, 3RS,4RS/3RS,4SR=1:1) of the title compound as a colorless oil.

$^1\text{H-NMR}$ (300MHz, CDCl_3 , 3RS,4RS-compound) : δ 7.05(dd, 1H), 6.82(dd, 1H), 6.65(t, 3H), 6.58(d, 2H), 6.40(d, 1H), 6.26(m, 2H), 6.05(s, 1H), 5.75(s, 1H), 5.16(s, 1H), 4.36(dd, 1H), 4.15(dd, 1H), 3.40-3.31(t, 2H), 3.15-2.80(m, 4H), 2.32-2.15(t, 4H), 1.75(m, 2H), 1.71-1.45(m, 4H)

Example 55

Synthesis of 4-hydroxy-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-4-[4-(piperidinoethoxy)phenyl]-2,3-dihydro-4H-benzopyran




4-(4-Hydroxyphenyl)-4-hydroxy-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-2,3-dihydro-4H-benzopyran (310mg, 0.59 mmol) prepared in Example 15, [1-(2-chloroethyl)piperidine] $\cdot$ HCl (176mg, 0.9 mmol) and K_2CO_3 (264 mg, 1.8 mmol) were dissolved in acetone (8ml) and then refluxed for 62 hours. The reaction solution was cooled to room temperature and, after adding water, extracted with ethyl acetate. The organic layer thus separated was dried over anhydrous magnesium sulfate, filtered and then concentrated under reduced

pressure to remove the organic solvent. The residue was separated by column chromatography (n-hexane:ethyl acetate = 1:2) to obtain 83mg (yield: 7%) of the title compound as a white foam.

$^1\text{H-NMR}$ (300MHz, CDCl_3) : δ 7.00(d, 2H), 6.78(d, 3H), 6.62(m, 4H), 6.37(dd, 2H), 5.25(d, 2H), 4.65(dd, 1H), 4.25(dd, 1H), 3.99(t, 2H), 3.38(dd, 1H), 3.31(d, 3H), 2.78(t, 2H), 2.43(m, 4H), 1.55(m, 4H), 1.35(m, 3H)

Example 56

Synthesis of 7-hydroxy-3-(4-hydroxyphenyl)-4-[4-(piperidinoethyloxy)phenyl]-2H-benzopyran



4-Hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-4-[4-(piperidinoethyloxy)phenyl]-2,3-dihydro-4H-benzopyran (83mg, 0.14 mmol) and pyridinium p-toulenesulfonate (214mg, 1.4 mmol) were dissolved in methanol (6 ml) and then refluxed for 12 hours. The reaction solution was cooled to room temperature and, after adding water, extracted with ethyl acetate. The organic layer thus separated was dried over anhydrous magnesium sulfate, filtered and then concentrated under reduced pressure to remove the organic solvent. The residue was separated by column chromatography (n-hexane:ethyl acetate = 1:4) to obtain 23mg (yield: 37%) of the title compound as a foam.

$^1\text{H-NMR}$ (300MHz, CDCl_3) : δ 6.95(d, 2H), 6.78(d, 2H), 6.65-6.48(m, 5H), 6.39(d, 1H), 6.21(dd, 1H), 5.00(s, 2H), 3.99(t, 2H), 2.76(t, 2H), 2.54(m,

4H), 1.62(m, 4H), 1.43(m, 2H)

Example 57

Synthesis of 7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-one

The process for preparing 7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-one described hereinafter corresponds to the process 7 depicted in the reaction scheme VII.

(1) To a solution of oxalic acid diethyl ester (18.8ml, 0.14 mol) in tetrahydrofuran (10ml) and benzene (10ml) was added sodium hydride (80% oil suspension, 6.5g, 0.22 mol) and then stirred for 10 minutes under argon atmosphere. A benzene solution (100ml) of 2-(p-methoxyphenyl)acetic acid ethyl ester (1) (27.0g, 0.14 mol) was added to the resulting solution and stirred for 3 days at room temperature. The reaction solution was quenched with aqueous 2N HCl solution and extracted with ether. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and then distilled under reduced pressure to remove the solvent. Thus, 48.0g of the crude product was obtained. The obtained crude product was dissolved in water (150ml) and 37% formalin (25ml, 0.31 mol) was added dropwise thereto. To the reaction mixture was added dropwise aqueous potassium carbonate solution (24g, 0.17 mol, 100ml) and then stirred for 24 hours. The reaction solution was extracted with ether, and the organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and distilled under reduced pressure to remove the solvent. The obtained crude product was then purified with silica gel column chromatography (ethyl acetate:hexane = 1:5) to obtain 27.0g (yield: 94%) of ethyl α -(4-methoxyphenyl)acrylate (2).

$^1\text{H-NMR}(\text{CDCl}_3)$: δ 7.37, 6.88(4H, AA'BB', J=9Hz, Ar-H), 6.25(1H, s, olefin-H), 5.82(1H, s, olefin-H), 4.28(2H, q, J=7Hz, CO_2CH_2), 3.82(3H, s, OCH_3), 1.33(3H, t, J=7Hz, CH_2CH_3)

(2) To tetrahydrofuran solution (150ml) of ethyl α -(4-methoxyphenyl)-acrylate (2) (26.0g, 0.13 mol) obtained above and 3-methoxybenzenethiol (15.6 ml, 0.13 mol) was added tetrahydrofuran solution (6.24ml, 1.0M, 6.24 mmol) of tetrabutylammoniumfluoride under argon atmosphere and then stirred for 10 minutes at room temperature. The reaction solution was distilled under reduced pressure to remove the solvent and the obtained crude product was then purified with silica gel column chromatography (ethyl acetate:hexane=1:5) to obtain 30.2g (yield: 70%) of ethyl 2-(4-methoxyphenyl)-3-(3-methoxyphenylthio)propionate (3).

$^1\text{H-NMR}(\text{CDCl}_3)$: δ 7.23-7.18(3H, m, Ar-H), 6.94-6.73(5H, m, Ar-H), 4.14(2H, q, $J=7\text{Hz}$, CO_2CH_2), 3.79(6H, s, $\text{OCH}_3 \times 2$), 3.74(1H, dd, $J=9$, 6Hz, CHCO_2), 3.55(1H, dd, $J=14$, 9Hz, 2-H), 3.21(1H, dd, $J=14$, 6Hz, 2-H), 1.21(3H, t, $J=7\text{Hz}$, CH_2CH_3)

(3) To acetone solution(300ml) of ethyl 2-(4-methoxyphenyl)-3-(3-methoxyphenylthio)propionate(3) (30.2g, 87.3 mmol) obtained above was added aqueous 6N-HCl solution (200ml) and then heated under refluxing for 60 hours. The reaction solution was extracted with ether, and the organic layer was alkalinized with aqueous 20% NaOH solution. Then the aqueous layer was separated, acidified with 20% HCl solution and extracted with ether. The ether layer was washed with saturated saline, dried over anhydrous magnesium sulfate and then distilled under reduced pressure to remove the solvent to obtain 25.4g (yield: 91%) of 2-(4-methoxyphenyl)-3-(3-methoxyphenylthio)propionic acid (4).


(4) To acetonitrile solution (120ml) of 2-(4-methoxyphenyl)-3-(3-methoxyphenylthio)propionic acid (4) (12.8g, 40.3 mmol) obtained above was added potassium carbonate (1.59g, 11.5 mmol) and phosphorus oxychloride (18.7ml, 200 mmol) at 0°C and then stirred for 18 hours at 60°C . The reaction solution was quenched with ice-water and extracted with ether. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and then distilled under reduced pressure to remove the solvent. The

obtained crude product was washed with ether to obtain 6.8g of the first crop of 7-methoxy-3-(4-methoxyphenyl)thiochroman-4-one (5). Further, the filtrate was concentrated and the residue was then purified with silica gel column chromatography (ethyl acetate:hexane = 1:3) to obtain 1.0g of the second crop of 7-methoxy-3-(4-methoxyphenyl)thiochroman-4-one (5) (total yield: 7.8g, 65%). NMR data of the compound (5) was identical to that described in Example 25.

The process for preparing the title compound, 7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-one, from the compound (5) obtained above is identical to that of Example 26.


Example 58

Synthesis of 7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-one



To acetic acid solution (15ml) of 7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-one (2.82g, 8.99 mmol) was added aqueous 48% HBr solution (13ml) and the mixture was heated under refluxing for 24 hours. The reaction solution was extracted with ethyl acetate, and the organic layer was washed with saturated aqueous sodium hydrogen carbonate solution and saturated saline, dried over anhydrous magnesium sulfate and then distilled under reduced pressure to remove the solvent. The crude product thus obtained was purified with silica gel column chromatography (ethyl acetate:hexane = 2:1) to obtain 2.46g (yield: 96%) of the title compound.


¹H-NMR(270MHz, d₆-DMSO) : δ 7.95(1H, d, J=9Hz, 5-H), 7.00, 6.65(4H, AA'BB', J=9Hz, Ar-H), 6.60(1H, dd, J=9, 2Hz, 6-H), 6.47(1H, d, J=2Hz, 8-H), 3.55(2H, ABq, J=12Hz, 2-H), 1.38(3H, s, CH₃)

Example 59**Synthesis of 7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methylthiochroman-4-one**

To dry acetone solution (100ml) of 7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-one (2.30g, 8.04 mmol) were added potassium carbonate (8.87g, 64.3 mmol) and methoxymethyl chloride (4.64ml, 61.5 mmol), and the mixture was heated under refluxing for 40 hours. After adding water, the reaction solution was extracted with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and then distilled under reduced pressure to remove the solvent. The crude product thus obtained was purified with silica gel column chromatography (ethyl acetate :hexane = 1:3) to obtain 2.65g (yield: 88%) of the title compound.


$^1\text{H-NMR}(\text{CDCl}_3)$: δ 8.18(1H, d, $J=9\text{Hz}$, 5-H), 7.14, 6.96(4H, AA'BB', $J=9\text{Hz}$, Ar-H), 6.80(1H, dd, $J=9, 2\text{Hz}$, 6-H), 6.74(1H, d, $J=2\text{Hz}$, 8-H), 5.35, 5.22(each 2H, each s, OCH_2OCH_3), 3.51, 3.44(each 1H, each d, $J=4\text{Hz}$, 2-H), 3.44(6H, s, $\text{OCH}_3 \times 2$), 1.47(3H, s, 3- CH_3)

Example 60**Synthesis of 4-(4-t-butyltrimethylsilyloxyphenyl)-4-hydroxy-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methylthiochroman**



Under argon atmosphere dibromoethane (0.11 ml, 1.28 mmol) was added dropwise to tetrahydrofuran suspension (5 ml) of magnesium turning (224 mg, 9.33 mmol) and the mixture was stirred for 10 minutes at 60 °C. At the same temperature, tetrahydrofuran solution (5 ml) of p-bromo-t-butyl dimethylsilyloxybenzene (2.30 g, 8.01 mmol) was added dropwise thereto and the mixture was heated under refluxing for 1.5 hours. To the resulting solution was added dropwise tetrahydrofuran solution (5 ml) of 7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methylthiochroman-4-one (1.00 g, 2.67 mmol) and the mixture was heated under refluxing for 3 hours. After adding saturated aqueous ammonium chloride solution, the reaction solution was extracted with ethyl acetate, and the organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and then distilled under reduced pressure to remove the solvent. The crude product thus obtained was purified with silica gel column chromatography (ethyl acetate:hexane = 1:4) to obtain 1.29 g (yield: 83%) of the title compound.

$^1\text{H-NMR}$ (270 MHz, CDCl_3) : δ 7.25-6.60 (11H, m, Ar-H), 5.15, 5.14 (each 2H, each s, OCH_2OCH_3), 4.28 (1H, d, $J=12\text{ Hz}$, 2-H), 3.48, 3.46 (each 3H, each s, $\text{OCH}_3 \times 2$), 2.73 (1H, d, $J=12\text{ Hz}$, 2-H), 1.45 (3H, s, 3- CH_3), 0.98 (9H, s, t-Bu), 0.19 (6H, s, $\text{SiCH}_3 \times 2$)

Example 61**Synthesis of (3RS, 4RS)-4-(4-t-butyldimethylsilyloxyphenyl)-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methylthiochroman**


To dichloromethane solution (30 ml) of 4-(4-t-butyldimethylsilyloxyphenyl)-4-hydroxy-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methylthiochroman (1.134g, 1.95 mmol) were added zinc iodide (1.367g, 4.9 mmol) and sodium cyanoborohydride (797mg, 12.7 mmol), and the resulting mixture was stirred for 2 hours at room temperature. After adding acetone (5ml) and water, the reaction solution was extracted with dichloromethane and the organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and distilled under reduced pressure to remove the organic solvent. The crude product thus obtained was purified with silica gel column chromatography (ethyl acetate:hexane = 1:4) to obtain 783mg (yield: 71%) of the title compound.

$^1\text{H-NMR}$ (270MHz, CDCl_3) : δ 7.34, 6.90(4H, AA'BB', $J=9\text{Hz}$, Ar-H), 7.00, 6.88(4H, AA'BB', $J=8\text{Hz}$, Ar-H), 6.72(1H, d, $J=8\text{Hz}$, 5-H), 6.71(1H, d, $J=3\text{Hz}$, 8-H), 6.57(1H, dd, $J=8, 3\text{Hz}$, 6-H), 5.12(2H, s, OCH_2OCH_3), 5.06(2H, d, $J=1\text{Hz}$, OCH_2OCH_3), 4.40(1H, s, 4-H), 3.46, 3.43(each 3H, each s, $\text{OCH}_3 \times$

2), 3.22(1H, d, J=13Hz, 2-H), 3.09(1H, d, J=13Hz, 2-H), 1.15(3H, s, 3-CH₃), 0.97(9H, s, t-Bu), 0.18(6H, s, SiCH₃×2)

Example 62

Synthesis of (3RS,4RS)-4-(4-hydroxyphenyl)-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methylthiochroman




Under argon atmosphere, tetrahydrofuran solution of tetrabutylammonium fluoride (1.0M, 2.27ml, 2.27 mmol) was added dropwise to tetrahydrofuran solution (35ml) of (3RS,4RS)-4-(4-*t*-butyldimethylsilyloxyphenyl)-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methylthiochroman (856mg, 1.51 mmol) at 0°C and the resulting mixture was stirred for 2 hours. After adding water, the reaction solution was extracted with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and then distilled under reduced pressure to remove the solvent. The crude product thus obtained was purified with silica gel column chromatography (ethyl acetate : hexane = 1:2) to obtain 682mg (yield: 100%) of the title compound.

¹H-NMR(270MHz, CDCl₃) : δ 7.32, 6.90(4H, AA'BB', J=8Hz, Ar-H), 7.02, 6.86(4H, AA'BB', J=8Hz, Ar-H), 6.72(1H, d, J=8Hz, 5-H), 6.70(1H, d, J=3Hz, 8-H), 6.57(1H, dd, J=8, 3Hz, 6-H), 5.12(2H, s, OCH₂OCH₃), 5.05(2H,

d, J=1Hz, OCH₂OCH₃), 4.76(1H, brs, OH), 4.40(1H, s, 4-H), 3.46, 3.43(each 3H, each s, OCH₃×2), 3.22(1H, d, J=13Hz, 2-H), 3.09(1H, d, J=13Hz, 2-H), 1.15(3H, s, 3-CH₃)

Example 63

Synthesis of 5-(5-chloropentylthio)-1,1,1,2,2-pentafluoropentane




Under argon atmosphere sodium methoxide-methanol solution (1.0M, 1.7 ml, 1.7 mmol) was added dropwise to methanol solution (5ml) of 4,4,5,5,5-pentafluoropentylthioacetate (400mg, 1.69 mmol) at room temperature and stirred for 20 minutes. To the resulting solution was added dropwise methanol solution (5ml) of 5-chloro-1-bromopentane (344mg, 1.86 mmol), and the mixture was stirred for 20 hours. After adding saturated aqueous sodium hydrogen carbonate solution, the reaction solution was extracted with ether. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and then distilled under reduced pressure to remove the solvent. The crude product thus obtained was purified with silica gel column chromatography (ethyl acetate:hexane = 1:5) to obtain 463mg (yield: 82%) of the title compound.

¹H-NMR(CDCl₃) : δ 3.54(2H, t, J=7Hz, ClCH₂), 2.59, 2.53(each 2H, each t, J=7Hz, CH₂SCH₂), 2.25-1.56(10H, m, alkyl-H)

Example 64

Synthesis of 5-(5-chloropentylsulfonyl)-1,1,1,2,2-pentafluoropentane




Aqueous solution (2ml) of oxone (865mg, 1.41 mmol) was added dropwise to tetrahydrofuran-methanol (2:1) solution (3ml) of 5-(5-chloropentylthio)-1,1,1,2,2-pentafluoropentane (210mg, 0.70 mmol) at 0°C and stirred for 5 hours. After adding aqueous sodium thiosulfate solution, the reaction solution was extracted with ether. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and then distilled under reduced pressure to remove the solvent. The crude product thus obtained was purified with silica gel column chromatography (ethyl acetate:hexane = 1:10) to obtain 209mg (yield: 90%) of the title compound.

$^1\text{H-NMR}(\text{CDCl}_3)$: δ 3.56(2H, t, $J=7\text{Hz}$, ClCH_2), 3.08-2.98(4H, m, $\text{CH}_2\text{SO}_2\text{CH}_2$), 2.40-1.60(10H, m, alkyl-H)

Example 65

Synthesis of (3RS,4RS)-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-4-[4-(5-(4,4,5,5-pentafluoropentylsulfonyl)pentyl)oxy]phenyl]thiochroman




5-(5-Chloropentylsulfonyl)-1,1,1,2,2-pentafluoropentane (27mg, 0.082 mmol), potassium carbonate (34mg, 0.25 mmol) and 18-crown-6 (21mg, 0.08

mmol) were added to benzene-dimethylformamide (1:1) solution (2ml) of (3RS,4RS)-4-(4-hydroxyphenyl)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methylthiochroman (37mg, 0.082 mmol) and then stirred for 8 hours at 100°C under argon atmosphere. After adding water, the reaction solution was extracted with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and distilled under reduced pressure to remove the solvent. The crude product thus obtained was purified using silica gel plate (ethyl acetate:hexane = 1:2) to obtain 41mg (yield: 67%) of the title compound.

¹H-NMR(270MHz, CDCl₃) : δ 7.37, 6.90(4H, AA'BB', J=9Hz, Ar-H), 7.06, 6.85(4H, AA'BB', J=8Hz, Ar-H), 6.77(1H, d, J=9Hz, 5-H), 6.70(1H, d, J=3Hz, 8-H), 6.56(1H, dd, J=9, 3Hz, 6-H), 5.12(2H, s, OCH₂OCH₃), 5.05(2H, d, J=1Hz, OCH₂OCH₃), 4.41(1H, s, 4-H), 3.94(2H, t, J=7Hz, ArOCH₂CH₂), 3.46, 3.42 (each 3H, each s, OCH₃×2), 3.22(1H, d, J=13Hz, 2-H), 3.09(1H, d, J=13Hz, 2-H), 3.05-2.99(4H, m, CH₂SO₂CH₂), 2.38-1.60(10H, m, alkyl-H), 1.15(3H, s, 3-CH₃)

Example 66

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-(5-(4,4,5,5,5-pentafluoropentylsulfonyl)pentyl)oxy)phenyl]thiochroman




Aqueous 6N-HCl solution (1ml) was added to tetrahydrofuran solution (1.5ml) of (3RS,4RS)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-

methyl-4-[4-(5-(4,4,5,5,5-pentafluoropentylsulfonyl)pentyl)oxy]phenyl]thiochroman (37mg, 0.050 mmol) and then stirred for one hour. After adding water, the reaction solution was extracted with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and then distilled under reduced pressure to remove the solvent. The crude product thus obtained was purified using silica gel plate (ethyl acetate:hexane = 1:2) to obtain 22mg (yield: 70%) of the title compound.

$^1\text{H-NMR}$ (270MHz, CDCl_3) : δ 7.27(2H, d, $J=8\text{Hz}$, Ar-H), 7.05(2H, d, $J=8\text{Hz}$, Ar-H), 6.79-6.68(5H, m, Ar-H), 6.48(1H, d, $J=3\text{Hz}$, 8-H), 6.37(1H, dd, $J=9, 3\text{Hz}$, 6-H), 4.62(2H, s, $\text{OH} \times 2$), 4.37(1H, s, 4-H), 3.94(2H, t, $J=7\text{Hz}$, $\text{ArOCH}_2\text{CH}_2$), 3.19(1H, d, $J=13\text{Hz}$, 2-H), 3.09(1H, d, $J=13\text{Hz}$, 2-H), 3.10-2.98(4H, m, $\text{CH}_2\text{SO}_2\text{CH}_2$), 2.38-1.60(10H, m, alkyl-H), 1.16(3H, s, 3- CH_3)

Example 67

Synthesis of (3RS,4RS)-4-[4-(4-chlorobutyl)oxy]phenyl]-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methylthiochroman




To acetone solution (2ml) of (3RS,4RS)-4-(4-hydroxyphenyl)-7-methoxy-

methoxy-3-[4-(methoxymethoxy)phenyl]-3-methylthiochroman (70mg, 0.15 mmol) were added 1-bromo-4-chlorobutane ($36\mu\text{l}$, 0.31 mmol) and potassium carbonate (64mg, 0.46 mmol), and the resulting mixture was heated under refluxing for 20 hours. After adding water, the reaction solution was extracted with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and then distilled under reduced pressure to remove the solvent. The crude product thus obtained was purified using silica gel plate (ethyl acetate:hexane = 1:2) to obtain 73mg (yield: 87%) of the title compound.

$^1\text{H-NMR}$ (270MHz, CDCl_3) : δ 7.34, 6.90(4H, AA'BB', $J=9\text{Hz}$, Ar-H), 7.05, 6.86(4H, AA'BB', $J=9\text{Hz}$, Ar-H), 6.77(1H, d, $J=9\text{Hz}$, 5-H), 6.70(1H, d, $J=3\text{Hz}$, 8-H), 6.55(1H, dd, $J=8, 3\text{Hz}$, 6-H), 5.12(2H, s, OCH_2OCH_3), 5.05(2H, d, $J=1\text{Hz}$, OCH_2OCH_3), 4.41(1H, s, 4-H), 3.95(2H, t, $J=7\text{Hz}$, $\text{ArOCH}_2\text{CH}_2$), 3.61(2H, t, $J=6\text{Hz}$, ClCH_2), 3.45, 3.42(each 3H, each s, $\text{OCH}_3 \times 2$), 3.22(1H, d, $J=13\text{Hz}$, 2-H), 3.09(1H, d, $J=13\text{Hz}$, 2-H), 2.00-1.88(4H, m, alkyl-H), 1.15(3H, s, 3- CH_3)

Example 68

Synthesis of (3RS,4RS)-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-4-[4-(4-piperidinobutyloxy)phenyl]thiochroman




Piperidine (40 μ l, 0.405 mmol) was added to ethanol solution (2 ml) of (3RS,4RS)-4-[4-(4-chlorobutyloxy)phenyl]-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methylthiochroman (73 mg, 0.135 mmol) and then heated under refluxing for 24 hours. The reaction solution was distilled under reduced pressure to remove the solvent. The crude product thus obtained was purified with amino silica gel chromatography (ethyl acetate:hexane = 1:5) to obtain 55 mg (yield: 69%) of the title compound.

$^1\text{H-NMR}$ (270MHz, CDCl_3) : δ 7.34, 6.90(4H, AA'BB', $J=9\text{Hz}$, Ar-H), 7.05, 6.86(4H, AA'BB', $J=9\text{Hz}$, Ar-H), 6.77(1H, d, $J=9\text{Hz}$, 5-H), 6.70(1H, d, $J=3\text{Hz}$, 8-H), 6.55(1H, dd, $J=8, 3\text{Hz}$, 6-H), 5.11(2H, s, OCH_2OCH_3), 5.05(2H, d, $J=1\text{Hz}$, OCH_2OCH_3), 4.41(1H, s, 4-H), 3.93(2H, t, $J=7\text{Hz}$, $\text{ArOCH}_2\text{CH}_2$), 3.61(2H, t, $J=6\text{Hz}$, ClCH_2), 3.45, 3.42(each 3H, each s, $\text{OCH}_3 \times 2$), 3.22(1H, d, $J=13\text{Hz}$, 2-H), 3.09(1H, d, $J=13\text{Hz}$, 2-H), 2.50-2.30(6H, m, $\text{NCH}_2 \times 3$), 1.85-1.35(10H, m, alkyl-H), 1.15(3H, s, 3- CH_3)

Example 69

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-(4-piperidinobutyloxy)phenyl]thiochroman




To tetrahydrofuran solution (3 ml) of (3RS,4RS)-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-4-[4-(4-piperidinobutyloxy)phenyl]thiochroman (55 mg, 0.093 mmol) was added aqueous 10% HCl solution (2 ml) and the resulting mixture was stirred for 20 hours. The reaction solution was distilled

under reduced pressure to remove the solvent. The crude product thus obtained was purified with amino silica gel chromatography (ethyl acetate) to obtain 25mg (yield: 53%) of the title compound.

$^1\text{H-NMR}$ (270MHz, CD_3OD) : δ 7.29(2H, d, $J=9\text{Hz}$, Ar-H), 7.08(2H, d, $J=8\text{Hz}$, Ar-H), 6.78(2H, d, $J=9\text{Hz}$, Ar-H), 6.73(1H, d, $J=8\text{Hz}$, Ar-H), 6.62(2H, d, $J=8\text{Hz}$, Ar-H), 6.40(1H, t, $J=2\text{Hz}$, 8-H), 6.30(1H, dd, $J=8, 2\text{Hz}$, 6-H), 4.40(1H, s, 4-H), 3.95(2H, t, $J=7\text{Hz}$, $\text{ArOCH}_2\text{CH}_2$), 3.31(2H, s, $\text{OH} \times 2$), 3.12(2H, s, 2-H), 2.50-2.30(6H, m, $\text{NCH}_2 \times 3$), 1.85-1.35(10H, m, alkyl-H), 1.11(3H, s, 3- CH_3)

Example 70

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-(4-piperidinobutyloxy)phenyl]thiochroman hydrochloride




To methanol solution (3ml) of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-(4-piperidinobutyloxy)phenyl]thiochroman (18mg, 0.093 mmol) was added aqueous 20% HCl solution (0.3ml) and the resulting mixture was stirred for 20 hours. The reaction solution was distilled under reduced pressure to remove the solvent and the crude product thus produced was dissolved in methanol. To the resulting solution was added Dowex 1- $\times$ 8 (240mg) and the mixture was stirred for 30 minutes. Dowex 1- $\times$ 8 was filtered off and the filtrate was then distilled under reduced pressure to remove the solvent. To the residue were added toluene (0.5ml), methanol (0.5ml) and 35% HCl (0.5ml)

and the mixture was distilled under reduced pressure to obtain 17mg (yield: 96%) of the title compound.

$^1\text{H-NMR}$ (270MHz, CD_3OD) : δ 7.30(2H, d, $J=9\text{Hz}$, Ar-H), 7.11(2H, d, $J=8\text{Hz}$, Ar-H), 6.81(2H, d, $J=9\text{Hz}$, Ar-H), 6.73(1H, d, $J=8\text{Hz}$, Ar-H), 6.63(2H, d, $J=8\text{Hz}$, Ar-H), 6.40(1H, t, $J=2\text{Hz}$, 8-H), 6.29(1H, dd, $J=8, 2\text{Hz}$, 6-H), 4.42(1H, s, 4-H), 4.01(2H, t, $J=7\text{Hz}$, $\text{ArOCH}_2\text{CH}_2$), 3.60-3.40(2H, m, NCH_2), 3.12(4H, brs, $\text{NCH}_2 \times 2$), 2.00-1.70(10H, m, alkyl-H), 1.11(3H, s, 3- CH_3)

Example 71

Synthesis of 1-(4,4,5,5,5-pentafluoropentyl)piperazine




Piperazine (777mg, 9.0 mmol) was added to ethanol solution (10ml) of 4,4,5,5,5-pentafluoropentyltoluenesulfonate (600mg, 1.81 mmol) and then heated under refluxing for 40 hours. After adding water, the reaction solution was extracted with ethyl acetate. The solvent was distilled off under reduced pressure from the extract to obtain 315mg (yield: 100%) of the title compound.

$^1\text{H-NMR}$ (CDCl_3) : δ 2.89(4H, t, $J=5\text{Hz}$, $\text{CH}_2\text{NH} \times 2$), 2.38(6H, m, $\text{NCH}_2 \times 3$), 2.20-1.95(2H, m, CF_2CH_2), 1.83-1.70(2H, m, $\text{CF}_2\text{CH}_2\text{CH}_2$)

Example 72

Synthesis of (3RS,4RS)-4-[4-(2-chloroethoxy)phenyl]-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methylthiochroman




To methyl ethyl ketone solution (3ml) of (3RS,4RS)-4-(4-hydroxyphenyl)-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-thiochroman (126 mg, 0.28 mmol) were added potassium carbonate (96mg, 0.70 mmol) and 1-bromo-2-chloroethane (115ml, 1.38 mmol), and the mixture was heated under refluxing for 70 hours. After adding water, the reaction solution was extracted with ethyl acetate. The extract was distilled under reduced pressure to remove the solvent and the crude product thus obtained was then purified using silica gel plate (ethyl acetate:hexane = 1:2) to obtain 69mg (yield: 48%) of the title compound.

¹H-NMR(270MHz, CDCl₃) : δ 7.34, 6.90(4H, AA'BB', J=9Hz, Ar-H), 7.08, 6.81(4H, AA'BB', J=9Hz, Ar-H), 6.89(1H, d, J=8Hz, 5-H), 6.71(1H, d, J=3Hz, 8-H), 6.55(1H, dd, J=8, 3Hz, 6-H), 5.12(2H, s, OCH₂OCH₃), 5.05(2H, d, J=1Hz, OCH₂OCH₃), 4.42(1H, s, 4-H), 4.19(2H, t, J=6Hz, ArOCH₂), 3.79(2H, t, J=6Hz, ClCH₂), 3.45, 3.43(each 3H, each s, OCH₃×2), 3.20(1H, d, J=13Hz, 2-H), 3.09(1H, d, J=13Hz, 2-H), 1.15(3H, s, 3-CH₃)

Example 73

Synthesis of (3RS,4RS)-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-4-[4-[2-(4-(4,4,5,5,5-pentafluoropentyl)piperazino)ethyloxy]phenyl]thio


-chroman

Under argon atmosphere 4-(4,4,5,5,5-pentafluoropentyl)piperazine (70mg, 0.4 mmol) was added to dimethylformamide solution (0.5ml) of (3RS,4RS)-4-[4-(2-chloroethoxy)phenyl]-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-thiochroman (69mg, 0.13 mmol) and then stirred for 8 hours at 80°C. After adding water, the reaction solution was extracted with ethyl acetate. The extract was distilled under reduced pressure to remove the solvent and the crude product thus obtained was then purified using amino silica gel plate (ethyl acetate:hexane = 1:2) to obtain 67mg (yield: 77%) of the title compound.

¹H-NMR(270MHz, CDCl₃) : δ 7.33, 6.90(4H, AA'BB', J=9Hz, Ar-H), 7.05, 6.79(4H, AA'BB', J=9Hz, Ar-H), 6.86(1H, d, J=8Hz, 5-H), 6.70(1H, d, J=3Hz, 8-H), 6.55(1H, dd, J=8, 3Hz, 6-H), 5.11(2H, s, OCH₂OCH₃), 5.05(2H, d, J=1Hz, OCH₂OCH₃), 4.41(1H, s, 4-H), 4.06(2H, t, J=6Hz, ArOCH₂), 3.45, 3.42(each 3H, each s, OCH₃×2), 3.22(1H, d, J=13Hz, 2-H), 3.09(1H, d, J=13Hz, 2-H), 2.80(2H, t, J=6Hz, OCH₂CH₂), 2.60, 2.59(each 4H, each brs, NCH₂CH₂N×2), 2.40(2H, t, J=7Hz, NCH₂), 2.20-1.95(2H, m, CF₂CH₂), 1.85-1.70(2H, m, CF₂CH₂CH₂), 1.15(3H, s, 3-CH₃)

Example 74

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{4-[2-(4-(4,4,5,5,5-pentafluoropentyl)piperazino)ethyloxy]phenyl}thiochroman dihydrochloride




To methanol solution (1ml) of (3RS,4RS)-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-4-{4-[2-(4-(4,4,5,5,5-pentafluoropentyl)piperazino)ethyloxy]phenyl}thiochroman (67mg, 0.10 mmol) was added aqueous 20% HCl solution (0.5ml) and the resulting mixture was then stirred for 20 hours at room temperature. The solvent was distilled off under reduced pressure to obtain the crude product which was then purified using amino silica gel plate (ethyl acetate:methanol= 10:1). After adding aqueous 20% HCl solution to the product, the solvent was distilled off under reduced pressure to obtain 62mg (yield: 85%) of the title compound.

¹H-NMR(270MHz, CD₃OD) : δ 7.30, 6.93(4H, AA'BB', J=9Hz, Ar-H), 7.09, 6.62(4H, AA'BB', J=9Hz, Ar-H), 6.72(1H, d, J=9Hz, 5-H), 6.40(1H, d, J=3Hz, 8-H), 6.30(1H, dd, J=8.2Hz, 6-H), 4.46(1H, s, 4-H), 4.39(2H, brs,

ArOCH₂CH₂), 3.90-3.60(10H, d, NCH₂ × 5), 3.31(2H, m, NCH₂), 3.12(2H, ABq, J=13Hz, 2-H), 2.40-2.00(4H, m, CF₂CH₂), 1.12(3H, s, 3-CH₃)

Example 75

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylsulfinyl)octyl]thiochroman




The title compound was prepared from 7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-one and 8-*t*-butyldimethylsilyloxyoctyne according to the same method as Examples 25 to 34.

¹H-NMR(270MHz, CDCl₃) : δ 7.22(d, J=8.6Hz, 2H, Ar-H), 6.86(d, J=8.3Hz, 3H, Ar-H and C5-H), 6.67(d, J=2.3Hz, 1H, C8-H), 6.50(dd, J=2.3Hz and 8.3Hz, 1H, C6-H), 3.65(d, J=11.6Hz, 1H, C2-H), 2.94(d, J=11.6Hz, 1H, C2-H), 2.90-2.50(m, 5H, 2 × CH₂S(O) and C4-H), 2.40-2.10(m, 4H, CH₂CH₂CF₂-CF₃), 1.66(m, 2H, alkyl-H), 1.21(s, 3H, C3-CH₃), 1.45-0.90(m, 12H, alkyl-H)

Example 76

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[10-(4,4,5,5,5-pentafluoropentylsulfinyl)decyl]thiochroman




The title compound was prepared from 7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-one and 10-*t*-butyldimethylsilyloxydecyne according to the same method as Examples 25 to 34.

¹H-NMR(270MHz, CDCl₃) : δ 7.21(d, J=8.6Hz, 2H, Ar-H), 6.86(m, 3H, Ar-H and C5-H), 6.69(s, 1H, C8-H), 6.51(d, J=6.9Hz, 1H, C6-H), 3.63(d, J=11.2Hz, 1H, C2-H), 2.94(d, J=11.2Hz, 1H, C2-H), 2.90-2.60(m, 5H, 2 × CH₂S(O) and C4-H), 2.40-2.10(m, 4H, CH₂CH₂CF₂CF₃), 1.90-1.70(m, 2H, alkyl-H), 1.17(s, 3H, C3-CH₃), 1.50-0.90(m, 16H, alkyl-H)

Example 77

Synthesis of (3RS,4RS)-7-hydroxy-3-phenyl-3-methyl-4-[9-(4,4,5,5,5-pentafluoro-pentylsulfinyl)nonyl]thiochroman




The title compound was prepared from 7-methoxy-3-phenyl-3-methylthiochroman-4-one and 9-*t*-butyldimethylsilyloxynonyne according to the same method as Examples 25 to 34.

¹H-NMR(270MHz, CDCl₃) : δ 7.39-7.33(m, 5H, Ar-H), 6.89(d, J=7.9Hz, 1H, C5-H), 6.69(s, 1H, C8-H), 6.58-6.48(m, 2H, C6-H and ArOH), 3.68(d, J=11.5Hz, 1H, C2-H), 3.01(d, J=11.5Hz, 1H, C2-H), 2.90-2.60(m, 5H, 2 × CH₂S(O) and C4-H), 2.40-2.10(m, 4H, CH₂CH₂CF₂CF₃), 1.67(m, 2H, alkyl-H), 1.26(s, 3H, C3-CH₃), 1.50-0.90(m, 14H, alkyl-H)


Example 78

Synthesis of (3RS,4RS)-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-penta-

fluoropentylsulfinyl)nonyl]thiochroman

The title compound was prepared from 3-(4-methoxyphenyl)-3-methylthiochroman-4-one and 9-t-butyltrimethylsilyloxynonyne according to the same method as Examples 25 to 34.

$^1\text{H-NMR}$ (270MHz, CDCl_3) : δ 7.24-6.81(m, 8H, Ar-H), 3.67(m, 1H, C2-H), 2.97(m, 1H, C2-H), 2.82-2.63(m, 5H, $2 \times \text{CH}_2\text{S}(\text{O})$ and C4-H), 2.40-2.10(m, 4H, $\text{CH}_2\text{CH}_2\text{CF}_2\text{CF}_3$), 1.78(m, 2H, alkyl-H), 1.40-0.80(m, 17H, alkyl-H and C3- CH_3)

Example 79**Synthesis of 7-methoxy-3-(4-methoxyphenyl)-3-methyl-4-(9-pentylthiononyl)-thiochroman**


To a solution of pentylthioacetate (430mg, 2.94 mmol) in methanol (10 mL) was added dropwise 1M solution of sodium methanolate (2.52mL, 2.52 mmol) at room temperature and stirred for one hour. A solution of 7-methoxy-3-(4-methoxyphenyl)-3-methyl-4-(9-methanesulfonyloxynonyl)thiochroman (204mg, 0.391 mmol) in tetrahydrofuran (5mL) was added dropwise to the

reaction mixture at the same temperature and stirred for overnight. The reaction mixture was quenched with water and then diluted with ethyl acetate. The organic layer was separated, washed with saturated NaCl solution, dried over magnesium sulfate, filtered and then concentrated. The concentrate was subjected to flash silica gel chromatography (hexane:ethyl acetate = 9:1) to obtain 230mg (yield: 95%, 3RS,4RS/3RS,4SR = 9:1) of the title compound as a yellow oil.

$^1\text{H-NMR}$ (270MHz, CDCl_3) : δ 7.29(d, $J=8.9\text{Hz}$, 2H, Ar-H), 6.91(m, 3H, Ar-H), 6.79(d, $J=2.6\text{Hz}$, 1H, C8-H), 6.58(dd, $J=8.2\text{Hz}$ and 2.6Hz , 1H, Ar-H), 3.82(s, 3H, OCH_3), 3.78(s, 3H, OCH_3), 3.64(d, $J=11.2\text{Hz}$, 1H, C2-H), 2.98(d, $J=11.6\text{Hz}$, 1H, C2-H), 2.74(brt, 1H, C4-H), 2.47(m, 4H, $2 \times \text{SCH}_2$), 1.55-0.89(m, 28H, C3- CH_3 and alkyl-H)

Example 80

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-(9-pentylthiononyl)thiochroman




To a solution of 7-methoxy-3-(4-methoxyphenyl)-3-methyl-4-(9-pentylthiononyl)thiochroman (230mg, 0.435 mmol) in dry dichloromethane (20ml) was added dropwise 1M solution of boron tribromide in dichloromethane (3.04ml, 3.04 mmol) at -78°C and stirred at the same temperature for one hour. Then the reaction mixture was warmed to room temperature and stirring was continued for additional 10 hours. The reaction mixture was quenched with water and then diluted with ethyl acetate. The organic layer was washed with saturated sodium hydrogen sulfide solution and water, dried over

magnesium sulfate, filtered and evaporated. The concentrate was subjected to flash silica gel chromatography (hexane:ethyl acetate = 9:1) to obtain 178mg (yield: 82%) of the title compound as a colorless oil.

$^1\text{H-NMR}$ (270MHz, CDCl_3) : δ 7.23(d, $J=8.6\text{Hz}$, 2H, Ar-H), 6.84(dd, $J=8.3\text{Hz}$ and 8.5Hz , 3H, Ar-H), 6.67(d, $J=2.6\text{Hz}$, 1H, C8-H), 6.50(dd, $J=8.3\text{Hz}$ and 2.3Hz , 1H, Ar-H), 5.12(brs, 1H, OH), 4.83(brs, 1H, OH), 3.62(d, $J=11.5\text{Hz}$, 1H, C2-H), 2.95(d, $J=11.5\text{Hz}$, 1H, C2-H), 2.68(brt, 1H, C4-H), 2.49(m, 4H, $2 \times \text{SCH}_2$), 1.58-0.89(m, 28H, C3-CH_3 and alkyl-H)

Example 81

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-(9-pentylsulfinonyl)thiochroman




A solution of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-(9-pentylthiononyl)thiochroman (178mg, 0.355 mmol) and sodium periodate (83mg, 0.390 mmol) in methanol (20ml) and water (5ml) was stirred at room temperature for 3.5 hours. The reaction mixture was quenched with water and then diluted with ethyl acetate. The organic layer was washed with water, dried over magnesium sulfate, filtered and concentrated. The concentrate was purified with preparative chromatography on silica gel plate (hexane:ethyl acetate = 1:1) to obtain 101mg (yield: 55%) of the title compound as a colorless oil.

$^1\text{H-NMR}$ (270MHz, CDCl_3) : δ 7.24(m, 3H, Ar-H), 6.86(dd, $J=8.4\text{Hz}$ and 2.4Hz , 2H, Ar-H), 6.66(d, $J=2.3\text{Hz}$, 1H, C8-H), 6.51(m, 1H, Ar-H), 5.67(s,


1H, OH), 5.43(s, 1H, OH), 3.62(dd, J=11.5Hz and 3.9Hz, 1H, C2-H), 2.76(m, 5H, C2-H and 2×S(O)CH₂), 1.71(m, 3H, alkyl-H), 1.42-0.90(m, 25H, C3-CH₃ and alkyl-H)

Example 82

Optical resolution of *rac*-(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman and synthesis of its sulfinyl derivative




The racemate of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman (205mg) was separated by preparative HPLC using a Chiralcel OD (2×25cm, available from Daicel Chemical Industries, LTD) and a UV detector at 280nm. The eluent was a (85:12:3:0.2) mixture of n-hexane/isopropanol/methanol/trifluoroacetic acid at flow rate of 9.0ml/min. The first eluted peak was, after evaporation of the solvent, the (-)-compound (Compound A, retention time: 19.0 min., 78.9mg, 84.3%ee) and the second was the (+)-compound (Compound B, retention time: 21.2 min., 64.9mg, 84.4%ee). Additionally the obtained (-) and (+)-compounds were purified by preparative HPLC under the same condition as in the first separation to give 47.6mg of Compound A [95.8%ee, [α]_D = -18.39 (c=1.000, CHCl₃)] and 34.5mg of Compound B [96.8%ee, [α]_D = +16.80 (c=1.000, CHCl₃)], respectively.



The obtained optically active Compounds A and B were oxidized to the corresponding sulfinyl Compound C (18.8mg, yield: 38% from 47.8mg of Compound A) and Compound D (9.8mg, yield: 29% from 34.5mg of Compound B) in a similar manner to Example 34.

Experiment 1 : Cell growth inhibiting activity

In this experiment, the cell growth inhibiting activity was determined by using the compounds of Examples 6, 7, 12 and 46 as the test compound and the known anti-estrogenic compound ZM189154 having the following structure (see, EP0124369 B1) as the control compound, according to the method described hereinafter.



ZM189154

MCF-7 cell lines (ATCC) were incubated in MEM (minimum essential medium) medium which is supplemented by 3% DCC (dextran coated charcoal)-treated FBS (fetal bovine serum) but does not contain phenol red, for one week. One day before drug administration, incubated MCF-7 cells were plated in 96-well plate in the concentration of 5×10^3 cells per well. After

the 96-well plate was incubated for one day, 0.1nM of estradiol and the test compound in the given concentration were added to each well. The plate was incubated for 7 days at 37°C and then MTT solution (Sigma) was added to each well in the amount of 15 μ l and allowed to react for 2 hours at 37°C. After the reaction is completed, the solubilizing/stopping solution (constitution: SDS, acetic acid, N,N-dimethylformamide) was added to each well in the amount of 100 μ l. Then, the absorption for each well at 570nm was measured by means of a plate reader. IC₅₀ value for inhibiting cell growth of 50% was calculated from the results as measured and described in the following Table 1.

Table 1. IC₅₀ value of the test compounds (nM)

Test compound	Compound of Example 6	Compound of Example 7	Compound of Example 12	Compound of Example 46	ZM189154
IC ₅₀ (nM)	277	54.8	524	33	77

From the results described in the above Table 1, it could be seen that the compound of the present invention exhibits cell growth inhibiting activity comparable to that of ZM189154 which has been known as anti-estrogenic compound in the prior art.

Experiment 2 : Anti-estrogenic activity (subcutaneous administration)

Anti-estrogenic activity of the test compound by subcutaneous administration was determined according to the method described hereinafter. In this experiment, the compounds of Examples 6, 7, 12 and 46 were used as the test compound and the known anti-estrogenic compound ZM189154 was used as the control compound as in Experiment 1.

The anti-estrogenic activity was determined by subcutaneously injecting

17 β -estradiol-benzoate (Sigma) to mice (ICR, weight 30 $\pm$ 2g), which were ovariectomized two weeks before, in an amount of 0.1 μ g/day, per mouse for 3 days and then measuring the degree that the test compound inhibits the increase of uterine weight. In this experiment, the test compound or the control compound was dissolved in peanut oil (Sigma) and injected subcutaneously for 3 days, once a day. After 24 hours from the last injection, the test animal was sacrificed and uterus was removed and weighed. The results as measured are described in the following Table 2.

Table 2.

Anti-estrogenic activity of the test compound in ovariectomized mice which were administered with 17 β -estradiol

Test compound/dosage (s.c., 3 days)		Inhibition (%)
Compound of Example 6	30 μ g/mouse	83.1
Compound of Example 7	30 μ g/mouse	87.0
Compound of Example 12	30 μ g/mouse	74.8
Compound of Example 46	30 μ g/mouse	16.7
Control compound ZM189154	30 μ g/mouse	73.8

From the results described in the above Table 2, it could be seen that the compounds of Examples 6, 7, 12 and 46 according to the present invention substantially inhibit the increase of uterine weight by estradiol to the degree rather superior to that of ZM189154 which has been known as anti-estrogenic compound in the prior art.

Experiment 3 : Anti-estrogenic activity (oral administration)

Oral anti-estrogenic activity of the test compound was determined according to the method described hereinafter. In this experiment, the compound of Example 7 was used as the test compound and the known anti-estrogenic compound ZM189154 was used as the control compound as in Experiment 2.

Anti-estrogenic activity was determined by subcutaneous administration of 17-estradiol-benzoate (Sigma) to mice (ICR, weight $30 \pm 2g$), which were ovariectomized 2 weeks before, in the amount of $0.1 \mu g/day$, per mouse for 3 days and then measuring the degree that the test compound inhibits the increase in uterus weight by stimulus with estradiol. In this experiment, the test compound or the control compound was suspended in 5% arabic gum solution and orally administered for 3 days, once a day. After 24 hours from the last administration, the test animal was sacrificed and uterus was removed and weighed. The results as measured are described in the following Table 3.

Table 3.

Anti-estrogenic activity of the test compound in ovariectomized mice which were administered with 17 β -estradiol (oral administration, 3 days)

Test compound/dosage (p.o., 3 days)		Inhibition (%)
Compound of Example 7	10mg/kg	68.1
ZM189154	10mg/kg	41.7

From the results described in the above Table 3, it could be seen that the compound according to the present invention administered via oral route substantially inhibits the increase of uterine weight by estradiol to the degree superior to that of ZM189154 which has been known as anti-estrogenic active

compound in the prior art.

Experiment 4 : Effect on bone mineral density of mouse femur

The effect of the compound of the present invention on bone mineral density of mouse femur was determined according to the method described hereinafter. In this experiment, the compounds of Example 7 was used as the test compound and the known anti-estrogenic compound ZM189154 was used as the control compound as in Experiment 2.

MCF-7 cells (ATCC) as human breast cancer cell were transplanted subcutaneously into BALB/c nude mouse (female, 6 weeks) and then estradiol was percutaneously injected twice a week in an amount of 0.01mg/mouse, for 3 weeks. Thereafter, estradiol was administered once a week in the same amount and the test compound or the control compound dissolved in 10% ethanol-90% peanut oil was administered. The control group received only vehicle. The test or control compound was administered subcutaneously in an amount of 1mg/0.1ml/mouse, once a week. After the administration of the test compound for 6 weeks, left femur was excised and soft tissue was removed therefrom. Then the bone mineral density (BMD) was measured in a SPA mode by means of dual energy X-ray absorptiometry DCS-600 (Aloka). For interpretation, femur was divided into ten in the direction of long axis and the mean bone marrow densities of 3, 4, and 3 fragments from proximal position were calculated. Each of the fragments was represented as proximal, middle or distal, respectively. The result as measured is described in the following Table 4.

Table 4.

Effect of the compound of the present invention on bone mineral density of mouse femur


	proximal BMD ^a	distal BMD	whole BMD
Control group	35.95 ± 1.50 ^b	37.80 ± 1.75	35.63 ± 0.97
Compound of Example 7	35.05 ± 2.05	36.29 ± 1.46	37.23 ± 1.41
ZM189154	34.19 ± 2.19	32.80 ± 1.30	34.57 ± 1.40

* a : mg/cm³ , b : mean ± SE

It is generally agreed that we focus on proximal and distal portion for elucidating the effect of anti-estrogen on bone metabolism. As can be seen from the results described in the above Table 4, the compound according to the present invention did little affect bone mineral density (BMD) at both proximal and distal portion and increased whole BMD by 4.5% when compared to control. In contrast, ZM189154 decreased BMD by 4.9%, 13.3% and 3.0% at proximal, distal and whole femur, respectively. There was no difference in inhibition of MCF-7 tumor growth between the test compound and ZM189154. Therefore, it could be identified that the compound of the present invention has little affect on BMD different from ZM189154 which has been known as anti-estrogenic active compound in the prior art.

WHAT IS CLAIMED IS :

1. A benzopyran derivative represented by formula (I):



and pharmaceutically acceptable salt thereof, in which

— represents a single bond or a double bond;





R_1 and R_2 independently of one another represent hydrogen, hydroxy or OR group, wherein R represents acyl or alkyl;

R_3 represents hydrogen, lower alkyl or halogeno lower alkyl, provided that

when — represents a double bond, R_3 is not present;

R_4 represents hydrogen or lower alkyl;

A represents a group of formula (a), (b), (c) or (d);



R_5 , R_6 and R_7 independently of one another represent hydrogen, alkyl, halogenoalkyl, alkenyl or halogenoalkenyl, or

R_6 and R_7 together with nitrogen atom to which they are bound can form a 4- to 8-membered heterocyclic ring which can be substituted with R_5 ;

X represents O, S or NR_8 , wherein R_8 represents hydrogen or lower alkyl;

m denotes an integer of 2 to 15;
 n denotes an integer of 0 to 2; and
 p denotes an integer of 0 to 4.

2. The benzopyran derivative of formula (I) as defined in claim 1,

wherein --- represents a single bond or a double bond; R_1 and R_2 independently of one another represent hydrogen, hydroxy or OR wherein R represents alkyl; R_3 represents hydrogen, C_1 - C_4 lower alkyl or halogeno- C_1 - C_4 lower alkyl, provided that when = represents a double bond, R_3 is not present; R_4 represents hydrogen or C_1 - C_4 lower alkyl; A represents a group of formula (a), (b), (c) or (d); R_5 , R_6 and R_7 independently of one another represent hydrogen, C_1 - C_6 alkyl, halogeno- C_1 - C_6 alkyl, C_2 - C_6 alkenyl or halogeno- C_2 - C_6 alkenyl, or R_6 and R_7 together with nitrogen atom to which they are bound can form a 5- to 6-membered heterocyclic ring which can contain 1 to 2 nitrogen atoms and can be substituted with halogeno- C_1 - C_6 alkyl; X represents O, S or NR_8 , wherein R_8 represents hydrogen or C_1 - C_4 lower alkyl; m denotes an integer of 4 to 12; n denotes an integer of 0 to 2 and p denotes an integer of 1 to 3.

3. The benzopyran derivative of formula (I) as defined in claim 2,

wherein --- represents a single bond or a double bond; R_1 and R_2 independently of one another represent hydrogen or hydroxy; R_3 represents hydrogen or C_1 - C_2 lower alkyl, provided that when = represents a double bond, R_3 is not present; R_4 represents hydrogen or C_1 - C_2 lower alkyl; A represents a group of formula (a), (b), (c) or (d); R_5 , R_6 and R_7 independently of one another represents hydrogen, C_1 - C_6 alkyl or halogeno- C_1 - C_6 alkyl, or R_6 and R_7 together with nitrogen atom to which they are bound can form piperazinyl or piperidino group which can be substituted with halogeno- C_1 - C_6 alkyl; X represents O or S; m denotes an integer of 4 to

12; n denotes an integer of 0 to 2 and p denotes an integer of 2.

4. The benzopyran derivative of formula (I) as defined in claim 3, wherein X represents S.

5. The benzopyran derivative of formula (I) as defined in claim 1, which is selected from the group consisting of:

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylthio)octyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylsulfinyl)octyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfonyl)nonyl]-2,3-dihydro-4H-benzopyran;

7-hydroxy-3-(4-hydroxyphenyl)-4-[4-(5-(4,4,5,5,5-pentafluoropentylthio)pentyl)oxy]phenyl]-2H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-thiochroman;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylthio)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylsulfinyl)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylsulfonyl)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran;


(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(2-piperidinoethylthio)nonyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(2-piperidinoethylsulfinyl)nonyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(5-(4,4,5,5,5-pentafluoro-

pentylthio)pentylloxy)phenyl]-2,3-dihydro-4H-benzopyran;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(5-(4,4,5,5,5-pentafluoropentylsulfinyl)pentylloxy)phenyl]-2,3-dihydro-4H-benzopyran;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(5-(4,4,5,5,5-pentafluoropentylsulfonyl)pentylloxy)phenyl]-2,3-dihydro-4H-benzopyran;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-(piperidinoethyloxy)phenyl]-2,3-dihydro-4H-benzopyran;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-(5-(4,4,5,5,5-pentafluoropentylsulfonyl)pentylloxy)phenyl]thiochroman;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-(4-piperidinobutyloxy)phenyl]thiochroman or its hydrochloride;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{4-[2-(4-(4,4,5,5,5-pentafluoropentyl)piperazino)ethyloxy]phenyl}thiochroman dihydrochloride;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylsulfinyl)octyl]thiochroman;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[10-(4,4,5,5,5-pentafluoropentylsulfinyl)decyl]thiochroman;
(3RS,4RS)-7-hydroxy-3-phenyl-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman;
(3RS,4RS)-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman;
(3RS,4RS)-7-methoxy-3-(4-methoxyphenyl)-3-methyl-4-(9-pentylthiononyl)thiochroman;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-(9-pentylthiononyl)thiochroman;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-(9-pentylsulfinynonyl)thiochroman;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman; and
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman.

6. A process for preparing the compound of formula (I):



and salt thereof, in which

==== represents a single bond or a double bond;





R₁ and R₂ independently of one another represent hydrogen, hydroxy or OR group, wherein R represents acyl or alkyl;

R₃ represents hydrogen, lower alkyl or halogeno lower alkyl, provided that

when ===== represents a double bond, R₃ is not present;

R₄ represents hydrogen or lower alkyl;

A represents a group of formula (a), (b), (c) or (d);



R₅, R₆ and R₇ independently of one another represent hydrogen, alkyl, halogenoalkyl, alkenyl or halogenoalkenyl, or


R₆ and R₇ together with nitrogen atom to which they are bound can form a 4- to 8-membered heterocyclic ring which can be substituted with R₅;

X represents O, S or NR₈, wherein R₈ represents hydrogen or lower alkyl;


m denotes an integer of 2 to 15;

n denotes an integer of 0 to 2; and


p denotes an integer of 0 to 4,
characterized in that a compound of formula (VIII):




wherein R_3 , R_4 and X are defined as above and P represents hydrogen or protected hydroxy group, is reacted with a compound of formula (IX):




wherein q denotes an integer of m-2 and TBS means t-butyldimethylsilyl group, to produce a compound of formula (VII):




wherein R_3 , R_4 , X, P, q and TBS are defined as above, the resulting compound of formula (VII) is reduced with sodium cyanoborohydride (NaBH_3CN) and zinc iodide (ZnI_2) to produce a compound of formula (VIA):



wherein --- , R_3 , R_4 , X, P, q and TBS are defined as above, the resulting compound of formula (VIA) is reduced with palladium on carbon (Pd/C) to produce a compound of formula (VIB):




wherein --- , R_3 , R_4 , X , P , m and TBS are defined as above, the resulting compound of formula (VIB) is then treated with pyridinium *p*-toluenesulfonate to produce a compound of formula (VIC):




wherein --- , R_3 , R_4 , X , P and m are defined as above, the resulting compound of formula (VIC) is reacted with a compound of formula (V):




wherein R_9 represents methyl or tolyl, to produce a compound of formula (IV):




wherein --- , R_3 , R_4 , X , P , m and R_9 are defined as above, the compound of formula (IV) is reacted with a compound of formula (III):




wherein W represents R_5 or $-(CH_2)_p-N\begin{smallmatrix} R_6 \\ R_7 \end{smallmatrix}$, wherein R_5 , R_6 , R_7 , n and p are defined as in formula (I), to produce a compound of formula (II):



wherein --- , R_3 , R_4 , X , W , P , m and n are defined as above, and the resulting compound of formula (II) is deprotected to produce a compound of formula (Ia):




wherein --- , R_3 , R_4 , X , W , m and n are defined as above, or the resulting compound of formula (Ia) is esterified or alkylated to produce a compound of formula (Ib):



wherein --- , R , R_3 , R_4 , X , W , m and n are defined as above.

7. A process for preparing the compound of formula (I):



and salt thereof, in which

==== represents a single bond or a double bond;





R₁ and R₂ independently of one another represent hydrogen, hydroxy or OR group, wherein R represents acyl or alkyl;

R₃ represents hydrogen, lower alkyl or halogeno lower alkyl, provided that

when ===== represents a double bond, R₃ is not present;

R₄ represents hydrogen or lower alkyl;

A represents a group of formula (a), (b), (c) or (d);



R₅, R₆ and R₇ independently of one another represent hydrogen, alkyl, halogenoalkyl, alkenyl or halogenoalkenyl, or


R₆ and R₇ together with nitrogen atom to which they are bound can form a 4- to 8-membered heterocyclic ring which can be substituted with R₅;

X represents O, S or NR₈, wherein R₈ represents hydrogen or lower alkyl;


m denotes an integer of 2 to 15;

n denotes an integer of 0 to 2; and


p denotes an integer of 0 to 4,
characterized in that a compound of formula (VIII):



wherein R_3 , R_4 and X are defined as above and P represents hydrogen or protected hydroxy group, is reacted with a compound of formula (XIV):




wherein TMS means trimethylsilyl group, to produce a compound of formula (XIII):




wherein R_3 , R_4 , X and P are defined as above, the resulting compound of formula (XIII) is reacted with a compound of formula (XII):




wherein Z represents halogen, Y represents halogen or hydroxy and m is defined as above, to produce a compound of formula (XI):




wherein R_3 , R_4 , X , P , Y and m are defined as above, the resulting compound of formula (XI) is reacted with a compound of formula (IIIa):



wherein R_5 and n are defined as above, to produce a compound of formula (X):




wherein R_3 , R_4 , R_5 , X , P , m and n are defined as above, and the resulting compound of formula (X) is deprotected to produce a compound of formula (Ic):




wherein P , R_3 , R_4 , R_5 , X , m and n are defined as above, or the resulting compound of formula (Ic) is esterified or alkylated to produce a

compound of formula (Id):



wherein --- , R, R₃, R₄, R₅, X, m and n are defined as above.

8. A process for preparing the compound of formula (I):



and salt thereof, in which

--- represents a single bond or a double bond;



R₁ and R₂ independently of one another represent hydrogen, hydroxy or OR group, wherein R represents acyl or alkyl;



R₃ represents hydrogen, lower alkyl or halogeno lower alkyl, provided that

when --- represents a double bond, R₃ is not present;

R₄ represents hydrogen or lower alkyl;

A represents a group of formula (a), (b), (c) or (d);





R_5 , R_6 and R_7 independently of one another represent hydrogen, alkyl, halogenoalkyl, alkenyl or halogenoalkenyl, or

R_6 and R_7 together with nitrogen atom to which they are bound can form a 4- to 8-membered heterocyclic ring which can be substituted with R_5 ;


X represents O , S or NR_8 , wherein R_8 represents hydrogen or lower alkyl;

m denotes an integer of 2 to 15;

n denotes an integer of 0 to 2; and

p denotes an integer of 0 to 4,

characterized in that a compound of formula (XI):



wherein R_3 , R_4 , X and m are defined as above, Y represents halogen or hydroxy and P represents hydrogen or protected hydroxy group, is reacted with a compound of formula (XVI):



wherein R_6 and R_7 are defined as above, to produce a compound of formula (XV):



wherein R₃, R₄, R₆, R₇, X, P and m are defined as above, and the resulting compound of formula (XV) is deprotected to produce a compound of formula (Ic):




wherein $\text{---}\text{---}\text{---}$, R₃, R₄, R₆, R₇, X and m are defined as above, or the resulting compound of formula (Ie) is esterified or alkylated to produce a compound of formula (If):



wherein $\overline{\text{---}}$, R, R₃, R₄, R₆, R₇, X and m are defined as above.

9. A process for preparing the compound of formula (Ig):



(Ig)

and salt thereof, in which

R_3 represents hydrogen, lower alkyl or halogeno lower alkyl;

R_4 represents hydrogen or lower alkyl;

W represents R_5 or $-(CH_2)_p-N\begin{smallmatrix} R_6 \\ R_7 \end{smallmatrix}$;

R_5 , R_6 and R_7 independently of one another represent hydrogen, alkyl, halogenoalkyl, alkenyl or halogenoalkenyl, or

R_6 and R_7 together with nitrogen atom to which they are bound can form a 4- to 8-membered heterocyclic ring which can be substituted with R_5 ;


X represents O, S or NR_8 , wherein R_8 represents hydrogen or lower alkyl;

m denotes an integer of 2 to 15;

n denotes an integer of 0 to 2; and


p denotes an integer of 0 to 4,

characterized in that a compound of formula (VIII):




(VIII)

wherein R_3 , R_4 and X are defined as above and P represents hydrogen or protected hydroxy group, is reacted with a compound of formula (XVI):




(XVI)

wherein TBS means t-butyldimethylsilyl group, to produce a compound of formula (XVII):




(XVII)

wherein R_3 , R_4 , X, P and TBS are defined as above, the resulting compound of formula (XVII) is reduced to produce a compound of formula (XVIII):



(XVIII)

wherein R_3 , R_4 , X, P and TBS are defined as above, the resulting compound of formula (XVIII) is deprotected to produce a compound of formula (XIX):




(XIX)

wherein R_3 , R_4 , X and P are defined as above, the resulting compound of formula (XIX) is reacted with a compound of formula (XX):




wherein W, m and n are defined as above and Z represents halogen, to produce a compound of formula (XXI):




wherein R₃, R₄, X, P, W, m and n are defined as above, and the resulting compound of formula (XIX) is deprotected to produce a compound of formula (Ig).

10. A process for preparing a compound of formula (XX):



in which



R₅, R₆ and R₇ independently of one another represent hydrogen, alkyl, halogenoalkyl, alkenyl or halogenoalkenyl, or

R₆ and R₇ together with nitrogen atom to which they are bound can form a 4- to 8-membered heterocyclic ring which can be substituted with R₅;

Z represents halogen

m denotes an integer of 2 to 15;

n denotes an integer of 0 to 2; and

p denotes an integer of 0 to 4,

characterized in that a compound of formula (XXII):



wherein Y represents halogen or hydroxy and Z and m are defined as above, is reacted with a compound of formula (XXIII):





wherein W is defined as above, to produce a compound of formula (XXIV):



wherein W, Y and m are defined as above; and the resulting compound of formula (XXIV) is then oxidized to produce the compound of formula (XX).

11. A process for preparing a compound of formula (XXVIII) or (XXIX):



in which

— represents a single bond or a double bond;

R represents acyl or alkyl;

R₃ represents hydrogen, lower alkyl or halogeno lower alkyl, provided that

when --- represents a double bond, R_3 is not present;

R_4 represents hydrogen or lower alkyl;


R_6 and R_7 independently of one another represent hydrogen, alkyl, halogeno-alkyl, alkenyl or halogenoalkenyl, or

R_6 and R_7 together with nitrogen atom to which they are bound can form a 4- to 8-membered heterocyclic ring which can be substituted with R_5 ;

X represents O, S or NR_8 , wherein R_8 represents hydrogen or lower alkyl; and

m denotes an integer of 2 to 15,


characterized in that a compound of formula (XXV):



wherein R_3 , R_4 and X are defined as above and P represents hydrogen or protected hydroxy group, is reacted with a compound of formula (XII):




wherein Z represents halogen, Y represents halogen or hydroxy and m is defined as above, to produce a compound of formula (XXVI):



wherein R_3 , R_4 , X , P , Y and m are defined as above, the resulting compound of formula (XXVI) is reacted with a compound of formula (XVI):




wherein R_6 and R_7 are defined as above, to produce a compound of formula (XXVII):




wherein R_3 , R_4 , R_6 , R_7 , X , P and m are defined as above, and the resulting compound of formula (XV) is deprotected to produce a compound of formula (XXVIII), or the resulting compound of formula (XXVIII) is esterified or alkylated to produce a compound of formula (XXIX).


12. A process for preparing a compound of formula (6):




characterized in that a compound of formula (1):




is reacted with oxalic acid diethyl ester and sodium hydride to produce a compound of formula (2):




the resulting compound of formula (2) is reacted with 3-methoxybenzenethiol represented by the formula:




to produce a compound of formula (3):



the resulting compound of formula (3) is reacted with hydrochloric acid to produce a compound of formula (4):



the compound of formula formula (4) is then cyclized to produce a compound of formula (5):



and the compound of formula (5) is reacted with methyl iodide in the presence of lithium diisopropylamide to produce the compound of formula (6).

13. A process for preparing a benzopyran derivative, said process being substantially as hereinbefore described with reference to any one of the examples.

14. A benzopyran derivative, substantially as hereinbefore described with reference to any one of the examples.

15. A benzopyran derivative, prepared by the process of any one of claims 6 to 13.

16. A pharmaceutical composition including or consisting of an effective amount of at least one compound according to any one of claims 1 to 5, 14 or 15, together with a pharmaceutically acceptable carrier, diluent or adjuvant therefor.

17. A method for the treatment or prophylaxis of a condition indicating the administration of an anti estrogenic compound in a mammal requiring said treatment or prophylaxis, which method includes or consists of administering to said mammal an effective amount of at least one compound according to any one of claims 1 to 5, 14 or 15, or of a composition according to claim 16.

18. A compound according to any one of claims 1 to 5, 14 or 15, or a composition according to claim 16 when used in the treatment or prophylaxis of a condition indicating the administration of an anti estrogenic compound.

19. A compound according to any one of claims 1 to 5, 14 or 15, or a composition according to claim 16 for use in the treatment or prophylaxis of a condition indicating the administration of an anti estrogenic compound.

20. The use of a compound according to any one of claims 1 to 5, 14 or 15, for the manufacture of a medicament for the treatment or prophylaxis of a condition indicating the administration of an anti estrogenic compound.

21. The method, compound, composition or use of any one of claims 17 to 20, wherein the condition is anovular infertility, breast cancer, endometrial cancer, uterine cancer, ovarian cancer, endometriosis, endometrial fibroma, benign prostate hypertrophy, or menstrual disorders.

Dated 16 May, 2000

C & C Research Laboratories

Patent Attorneys for the Applicant/Nominated Person

SPRUSON & FERGUSON

